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The fragile X family of disorders is associated with CGG repeat expansions in the 5’UTR of the 
FMR1 gene on the X chromosome. The full mutation (~200 CGG repeats) causes 
hypermethylation of the DNA that results in silencing of the FMR1 transcript and Fragile X 
Syndrome (FXS), a protein loss of function mechanism that results in early onset mental 
retardation. The premutation (~55-200 CGG repeats) is associated with Fragile X Tremor Ataxia 
Syndrome (FXTAS), a late onset neurodegenerative disorder, and Fragile X primary ovarian 
insufficiency (FXPOI), causing early menopause from reduced estrogen levels. The purpose of 
this thesis is to determine if FXTAS and FXPOI are protein loss of function disorders or RNA 
gain of function disorders.  
RNAs containing an hnRNP A2 response element (A2RE) are localized and transported in 
discrete ribonucleoprotein particles called hnRNP A2 granules that are organized by a series of 
multivalent interactions. We show that RNAs containing CGG repeat sequences are also 
localized in hnRNP A2 granules. Additionally, exogenous premutation CGG repeat RNA 
microinjected in mouse hippocampal neurons or mouse oocytes inhibits granule RNA 
translation. Endogenous premutation CGG repeats in the FMR1 gene in human fibroblast cells 
from females at risk for FXPOI also inhibit granule RNA translation. We suggest that CGG 
repeat RNAs encoding calcium regulatory proteins may be in RNA granules and show that CGG 
repeat RNAs in premutation human fibroblast cells affect calcium homeostasis which may 
contribute to FXTAS and FXPOI pathogenesis. Additionally, premutation CGG repeat RNA 
containing the 5’UTR, a small part of the ORF and part of intron 1 from FMR1 in the transgenic 
TG296 mouse does not inhibit granule RNA translation. We interpret these results to show that 
FXTAS and FXPOI are granule based phenomena and RNA gain of function disorders. We  
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suggest two mechanisms for RNA gain of function mechanisms, sequestration of translational 
machinery, supported by ribosomal profile data and activation of the double stranded binding 
protein, protein kinase R (PKR). Differences in the magnitude of translational inhibition by CGG 
repeat RNA in neurons, fibroblasts and oocytes suggests that activation of PKR is most likely 
the pathogenic mechanism for FXTAS and FXPOI. 
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RNA localization 
RNA localization is a specialized method for obtaining distinct gene expression patterns in 
polarized cells such as neurons and oligodendrocytes (1). In situ hybridization of RNA 
localization in Drosophila during early development reveals that more than 70% of transcripts 
exhibit characteristic localization patterns, suggesting that most RNAs are actually localized and 
that RNA localization is necessary for local protein expression and function (2). In fact, 
localization of mRNAs has been observed in multiple cell types providing functional advantages. 
For example, bicoid RNA is localized to the anterior pole in developing Drosophila oocytes and 
is necessary for patterning of the head and thorax (3). Oskar RNA is localized to the posterior 
pole of the Drosophila oocyte during formation of the germ plasm. Oskar protein localization 
directs localization of a second RNA, nanos, which is necessary for proper abdominal patterning 
(4). Mammalian cells exhibit RNA localization as well. Actin RNA is concentrated at the 
lamellopodia of skeletal myoblasts and fibroblasts from chick embryos and correlates with 
localized actin protein expression (5). Also, myelin basic protein (MBP) RNA is localized to the 
peripheral processes in cultured mouse oligodendrocytes and in vivo and correlates with myelin 
formation (6, 7). Understanding the mechanism for RNA localization is critical to understanding 
localized translation and localized protein function. 
RNA localization occurs via trans-acting protein-RNA interactions driven by RNA localization 
elements. One particular localization element, an eleven nucleotide sequence known as the 
hnRNP A2 Response Element (A2RE)  (GCCAAGGAGCC), first identified as a localization 
signal in MBP RNA (7), drives dendritic localization of several different RNAs in neurons and 
oligodendrocytes. Similar sequences have been identified in RNAs encoding proteins involved 
in synaptic plasticity such as calcium, calmodulin-dependent protein kinase 2A (CAMK2A), 
neurogranin (NRGN) and activity regulated cytoskeletal associated (ARC) protein, (8). While the 
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A2RE and signals like it are necessary for localization of specific RNAs, other interactions are 
also required for RNA localization. 
hnRNP A2 RNA granules 
Localization signals are not sufficient for local translation. In addition, a series of multivalent 
molecular interactions are necessary to organize the RNA molecules with trans-acting proteins 
into units called RNA granules (9), which move via molecular motors to sites of local translation 
(10). Affinity purification of the binding partners for the A2RE, followed by protein sequencing 
and mass spectrometry identified heterogeneous nuclear ribonucleoprotein A2 (hnRNP A2) as 
the major protein that binds the A2RE (11). In turn, yeast-two-hybrid screening identified a 
binding partner for hnRNP A2 known as tumor overexpressed gene (TOG) (12). Fluorescence 
correlation spectroscopy (FCS) and surface plasmon resonance (SPR) indicated that TOG 
protein contains seven α-helical hnRNP A2 binding domains, suggesting that TOG may serve 
as a multivalent scaffold for hnRNP A2 binding during granule assembly (13) (Figure 1). 
hnRNP A2, found in abundance in both the nucleus and cytoplasm, is a member of the hnRNP 
family of proteins that are found in the RNA splicing complex, and are believed to be involved in 
selection of the RNA splice site depending on the abundance of the protein (14). hnRNP A2 is 
also believed to function as an adapter between telomeric DNA and telomerase, thus protecting 
DNA from degradation (15). TOG is a microtubule binding protein required for proper spindle 
pole formation during mitosis (16). Additionally, TOG is necessary for organization of 
microtubule minus ends at spindle poles, centrosome integrity and bipolarity of spindle poles 
(17). 
TOG is colocalized with A2RE RNA and hnRNP A2 in RNA granules (12). This suggests that 
multivalent interactions of TOG characterized in vitro mediate RNA granule assembly in vivo. In  
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Figure 1: hnRNP A2 RNA granules consist of multivalent interactions. TOG protein can act 
as a scaffold for hnRNP A2 binding each of its seven binding domains. hnRNP A2 also has two 
RNA binding domains. The A2RE sequence and CGG repeats can bind to these domains. 
These are the interactions that form hnRNP A2 RNA granules.  
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addition to the key components, A2RE RNA, hnRNP A2 and TOG, hnRNP A2 RNA granules 
also contain many translational components, including Arginyl-tRNA synthetase, elongation 
factor 1a and ribosomal RNA (18). Single molecule imaging indicates that hnRNP A2 RNA 
granules serve as sites for translation in dendrites and at synapses (19). 
As previously mentioned, A2RE RNAs that are associated with synaptic plasticity are found in 
hnRNP A2 RNA granules. In particular, I will focus on the immediate early gene ARC, which is 
involved in regulation of actin dynamics, promoting long term potentiation (LTP) consolidation 
(20) and also binds to dynamin and endophilin to mediate endocytosis of AMPA receptors 
during LTD (21). Interaction of ARC with the cytoskeleton makes it a good reporter for local 
translation because newly synthesized ARC is anchored to the cytoskeleton in the vicinity of the 
site of translation. ARC is also involved in metabotropic glutamate receptor (mGluR) dependent 
Long Term Depression (LTD) by interacting with components of the endocytic machinery, 
dynamin and endophilin 2/3, resulting in internalization of AMPA receptors (AMPARs) (20). 
However, A2RE RNAs are not the only RNAs that bind hnRNP A2 and are therefore localized to 
hnRNP A2 RNA granules. CGG repeat containing RNAs also bind to hnRNP A2 (22, 23) (Figure 
1). Less than a dozen different A2RE RNAs have been identified, but there are more than  200 
different CGG repeat containing RNAs in the human exome (24), which suggests that CGG 
repeat RNAs may be the predominant RNAs in hnRNP A2 RNA granules. In chapter 2, we will 
show that some granules have up to ten fold more CGG RNA than ARC RNA, a reporter for 
A2RE RNAs in hnRNP A2 RNA granules. 
Other types of RNA granules 
hnRNP A2 RNA granules are one of many categories of RNA granules. Understanding the 
mechanisms and functions of hnRNP A2 RNA granules aids in understanding other RNA 
transport granules and perhaps even other classes of granules. As previously mentioned, 70% 
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of RNAs in Drosophila embryos exhibit characteristic granule-like localization patterns (2). 
Approximately 35 discrete RNA localization patterns have been identified, which may 
correspond to types of RNA granules.  Each type of RNA granule presumably contains RNAs 
with characteristic cis-acting localization sequences, which bind to cognate RNA binding 
proteins, which in turn associate with cognate multivalent scaffold proteins to form the RNA 
granule (9). Different types of RNA granules may have different functions.  In addition to RNA 
transport granules, three other major types of RNA granules have been identified in living cells, 
polar granules (P granules), processing bodies (P bodies) and stress granules. Investigating 
granule assembly, localization and function of A2 granules may be relevant to understanding 
assembly, localization and function of other granule types. 
P granules are ribonucleoprotein particles (RNPs) that contain maternal RNAs that specify germ 
cell differentiation (25). The function of P granules is to regulate timing of translation of maternal 
RNAs to control the development of germ cells and establish the germ line (25). P granules 
have been identified in germ cells from Miastor metraloas, Xenopus laevis, Drosophila 
melanogaster and Caenorhabditis elegans (25). 
P bodies, sometimes confused with P granules, are somatic cell granules containing 
components of the 5'–>3' mRNA decay machinery, the nonsense-mediated decay pathway, and 
the RNA-induced silencing complex (25). Assembly of P bodies is increased in response to 
cellular stress, and is mediated by the colocalization of translationally silent RNAs with 
decapping machinery (26). Although the function of P bodies is debatable, the local 
concentration of translationally silent RNAs is increased in P bodies, which may facilitate their 
function (26).  
Stress granules are functional RNPs that decrease translation of housekeeping genes but 
increase translation of molecular chaperones and enzymes involved in repair in response to 
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environmental stress (25). The key component of stress granule assembly is eukaryotic 
initiation factor 2α (EIF2α) which is phosphorylated during environmental stress (25). This 
prevents formation of the EIF2–GTP–tRNAi Met ternary complex, inhibiting AUG initiated 
translation and promoting polysome disassembly (25). It is believed that some RNAs shuttle 
between stress granules and P bodies suggesting that these are functionally distinct types of 
granules (26). 
Eukaryotic translation 
One of the most important cellular processes that occurs in hnRNP A2 RNA granules is 
translation. Translation is the process of producing peptides or proteins from an mRNA 
sequence. It is believed that this process initiates with ribosome scanning in which the 40S 
subunit of a ribosome carrying a Met-tRNAimet and initiation factors binds to the 5’ end of an 
mRNA and scans in a 5’-3’ direction until encountering the first AUG (start codon) in an 
appropriate context (27). The scanning complex is known as the 43S preinitiation complex, and 
consists of EIF2, which binds to the Met-tRNAimet and GTP, EIF1A, which is involved in transfer 
of EIF2 to the 40S subunit, EIF5, which activates the GTPase activity of EIF2, EIF1, which is 
involved in recognition of the start codon and EIF3 which prevents elongation (28). In the 
nucleus, mRNAs are capped with a m7GpppN structure (29) that is believed to recruit the 40S 
ribosomal subunit (28). EIF4E binds to the 5’ cap (30). EIF4G then forms a bridge between 
EIF4E, EIF3 on the 40S ribosomal subunit (31) and EIF4A (32) which likely has helicase activity 
to unwind secondary structure in the 5’-untranslated region (5’-UTR) during scanning (33). Upon 
recruitment of the 43S preinitiation complex, the 48S initiation complex forms and scans the 
mRNA until finding the first AUG, followed by the processes of initiation, elongation and 
termination. 
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RNA secondary structure and translation  
During translation, translocation of the ribosome along the mRNA is dependent on the mRNA 
helicase activity of the ribosome, which is believed to unwind secondary structures in the mRNA 
(34). As a result of this process, the ribosome undergoes a series of translocation-pause-
translocation steps that are dependent on the RNA hairpin structure (35, 36). Highly structured 
mRNA molecules have decreased translation rates (35, 36). Additionally, G-quadruplex 
structures in either the 5’-UTR or the open reading frame (ORF) of mRNA in human cells 
decreases cellular translation of transfected mRNA (37). Trinucleotide repeat sequences, which 
are found in certain RNAs in hnRNP A2 RNA granules can form secondary structures and 
quadruplex structures, suggesting that they may regulate granule RNA translation.  
hnRNP A2 RNA granule RNA translation may also be regulated by translation factors encoded 
by granule RNAs.  These include EIF2α RNA containing an A2RE sequence and multiple other 
translation factor RNAs containing CGG repeats.  Eukaryotic translation initiation factor 2 alpha 
kinase 2, EIF2AK2, also known as protein kinase R (PKR), contains CGG repeats in the 5’-UTR 
which bind to hnRNP A2 and mediate localization in A2 RNA granules (21). PKR is a 
serine/threonine kinase that autophosphorylates when bound to double stranded RNA (38).  
CGG repeat sequences in hnRNP A2 granule RNAs can form double stranded secondary 
structures that can activate PKR. Activated PKR can phosphorylate EIF2α, which may regulate 
conventional translation in hnRNP A2 RNA granules (39) (Figure 2).  
In CGG repeat expansion disorders, such as fragile X tremor ataxia syndrome (FXTAS), the 
CGG repeat expansions may form stable CGG repeat secondary structures, which may 
increase PKR activation. In chapter 2, we will show that introducing one or more CGG repeat 
RNAs into an hnRNP A2 RNA granule inhibits translation of all other RNAs in that granule in  
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Figure 2: PKR activation by double stranded RNA prevents translation. Inactive PKR is 
folded in such a way that the double stranded RNA binding domains block autophosphorylation 
(40). Upon binding to double stranded RNA, autophosphorylation activates PKR and allows it to 
facilitate phosphorylation of EIF2α (38). Phosphorylated EIF2α forms an inactive complex with 
EIF2B which prevents translation (39).  
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trans, demonstrating that CGG repeat RNA regulates granule RNA translation. Whether 
translation in hnRNP A2 RNA granules is regulated directly by CGG repeats or indirectly by 
activation of a translational regulator, CGG repeat secondary structure may serve as a 
regulatory element in mRNA translation. 
Nucleotide repeat expansions 
Trinucleotide repeat regions in RNA molecules can be highly structured. Multiple different 
neurological disorders, including Huntington disease, spinal and bulbar atrophy and many 
ataxias are associated with trinucleotide repeats in different genes. A unique characteristic of 
each of these disorders is that individuals of successive generations have decreased age of 
onset and increased severity, which is known as “genetic anticipation” (41). Genetic anticipation 
is associated with increasing expansions of trinucleotide repeats in DNA (41). Approximately 30 
human disorders have been identified that are associated with trinucleotide, tetranucleotide, 
pentanucleotide and dodecanucleotide repeat expansions (41). In most cases increasing repeat 
number above a threshold of ~100-150 repeats results in destabilization of the repeats, and 
further expansions become more likely (41). 
Two causes for repeat instability in successive generations have been identified, replication-
dependent and repair-dependent (42). Replication-dependent instability occurs via DNA 
polymerase slippage when the nucleotide repeat sequence misaligns, forming an extrahelical 
loop that bypasses repair (42). On the daughter strand, this results in an expansion, while on 
the template strand, it results in a deletion (42). Repair-dependent instability can occur in two 
different ways. First, MutSβ, a DNA mismatch repair protein, recognizes and binds to slipped 
DNA, protecting it from repair and thus enhancing replication-dependent instability (43). Second, 
during base excision repair to remove oxidized guanines, a single stranded break is formed 
followed by gap filling synthesis by the polymerase (44). This displaces the single strand of the 
DNA being repaired (44). If the repair occurs in a region with nucleotide repeats, the single 
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strand may fold back on itself in a hairpin structure. When ligation subsequently occurs this can 
result in an expansion (44). These mechanisms suggest that any repeat RNA has the potential 
to expand, although thus far expansions have only been identified in ~ 30 different genes. 
The majority of trinucleotide repeats can form secondary structures, with stability based on GC 
content (45). Trinucleotide repeat motifs can be separated into four structural classes: 
unstructured, semi-stable hairpin, stable hairpin and quadruplex. For example, CGG and CCG 
repeats form stable hairpin structures (45) which may impede translocation of the ribosome or 
interact with translation factors. In chapter 2 we will show that ribosomes accumulate in the 
vicinity of CGG repeats in FMR1 RNA. The human exome contains 878 trinucleotide repeat 
containing genes (24), suggesting that secondary structure regulation of translation is a 
common occurrence in the human exome.  
RAN translation 
In addition to conventional translation, repeat containing RNAs can undergo an unconventional 
nonAUG form of translation called repeat associated non-ATG (RAN) translation (46). RAN 
translation in the absence of an AUG start codon occurs at lower rates than conventional AUG 
initiated translation and can occur in multiple and bidirectional reading frames (46). RAN 
translation of CAG repeats in spinocerebellar ataxia type 8 (SCA8) and myotonic dystrophy type 
1 (DM1) results in synthesis of polyglutamine, polyalanine and polyserine peptides (48).  RAN 
translation of CGG repeats in fragile X mental retardation 1 (FMR1) RNA in FXTAS, results in 
polyglycine and polyalanine tracts (47). Potentially, CGG repeats in FMR1 may produce 
polyarganine tracts as well. RAN translation in C9orf72 RNA in amyotrophic lateral sclerosis 
(ALS) and frontotemporal dementia (FTD), results in synthesis of six RAN proteins (antisense: 
Pro-Arg, Pro-Ala, Gly-Pro; and sense: Gly-Ala, Gly-Arg, Gly-Pro) (48). RAN translation products 
may contribute to pathogenesis of repeat disorders (46-48). 
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FXTAS, FXPOI and FXS 
CGG repeat expansions in the 5’-UTR of the FMR1 gene are associated with a family of 
disorders known as Fragile X disorders. In unaffected individuals, the number of CGG repeats in 
the FMR1 gene is usually less than 55. However, when the repeats are expanded to a 
premutation level between 55 and 200, individuals are often affected by FXTAS or Fragile X 
Primary Ovarian Insufficiency (FXPOI). Expansions above 200 usually result in Fragile X 
Syndrome (FXS) (49). 
FXTAS is a late onset neurodegenerative disorder affecting primarily males as the FMR1 gene 
is located on the X chromosome. The average age of onset for FXTAS is 61.6 ± 7.9 years (50). 
The disorder is characterized by progressive cerebellar ataxia, intention tremors, Parkinsonism, 
cognitive decline and sometimes psychiatric disturbances and autonomic and peripheral 
neuropathy (50). Approximately 1 in 260 females and 1 in 813 males are carriers. Penetrance is 
40% in males over the age of 50 while only 8% in females over the age of 40 (50). The disorder 
is also characterized by cerebellar and cerebral white matter loss that affects males more than 
females (50).  
Primary ovarian insufficiency is a disorder affecting ~1% of the female population under the age 
of 40 resulting in reproductive problems and early menopause (51).  Premutation Fragile X 
alleles occur in ~7% of sporadic POI and ~21% of familial POI (51). FXPOI individuals have 
decreased ovarian function that is dependent on the number of CGG repeats (51). The resultant 
symptoms include decreased numbers of growing follicles in ovaries and altered serum 
hormone levels, including Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and 
17β-estradiol (52). Additionally, LH-induced ovulation-related gene expression is altered (52). In 
chapter 3, we show that translation of Venus-ARC RNA is inhibited in mouse oocytes coinjected 
with CGG99 RNA, suggesting that translation inhibition in oocytes may contribute to FXPOI 
pathogenesis. 
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Fragile X Syndrome is the most common cause of inherited intellectual disability and autism in 
children (53). It has a frequency of 1:4000 males and 1:6000 females (53). Lack of FMRP, a 
translation regulator, is believed to stimulate protein expression following mGluR activation 
resulting in increased AMPAR internalization and LTD (54). 
Both FXTAS and FXPOI are considered toxic RNA gain-of-function disorders because the levels 
of FMR1 transcript are increased while the levels of fragile X mental retardation protein (FMRP) 
protein are decreased (50, 51). Fragile X Syndrome is considered a protein loss-of-function 
disorder since hypermethylation of the DNA causes silencing of the transcript and thus absence 
of the resulting protein (54). 
FMRP function and targets 
FMRP is a protein that is most commonly associated with Fragile X disorders as described 
previously, however, it also serves an important regulatory function in the cell. Two K homology 
domains (KH domains) that recognize and bind RNA were identified in a region of FMRP that is 
not involved in alternative splicing (55). These KH domains bind stoichiometrically to ~4% of 
human fetal brain messages (55). Importantly, FMRP also binds to its own message (55). 
Understanding the function of FMRP is essential since FMRP plays such an integral role in 
causing Fragile X related disorders. Multiple potential FMRP binding partners have been 
identified via high throughput microarray analysis (56, 57). 
Approximately 70% of FMRP-binding transcripts identified by microarray analysis were found to 
contain G-quartet structures, suggesting that this may be a target for FMRP binding (57). In 
addition to two KH domains, FMRP contains a C-terminal RGG box thought to enhance 
sequence specific binding at the KH domains (58, 59). The RGG box was found to bind 
specifically to G-quartet motifs (58, 59). 
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The function of FMRP in relation to its binding to RNAs is unknown. However, FMRP 
suppresses translation of brain poly(A) RNA in rabbit reticulocyte lysate in a dose dependent 
manner (60). Specifically, translation of RNAs that bind FMRP is suppressed, while translation 
of RNAs that do not bind FMRP is not suppressed (60). Additionally, the phosphorylation state 
of FMRP is important to its function because phosphorylated FMRP tends to associate with 
stalled polyribosomes while non-phosphorylated FMRP tends to associate with actively 
translating RNAs (61). Since FMRP phosphorylation state is altered in conjunction with synaptic 
activity, this may represent a mechanism for translation regulation in RNA granules in response 
to synaptic activity (61). 
TMPyP4 
Tetra(4-N-methyl-pyridyl)porphyrin (TMPyP4) is a non-toxic, membrane-permeant porphyrin ring 
compound. TMPyP4 alters secondary structure of CGG99 RNA and rescues translation of CGG 
repeat RNA in vitro and in Human Embryonic Kidney 293 cells (62). TMPyP4 alters the 
secondary structure in the 5’-UTR of MT3-MMP mRNA and rescues in vitro translation of the 
RNA (63). These results suggest that TMPyP4 can be used for investigating the effect of CGG 
repeat secondary structure on translation. In chapter 2, we show that TMPyP4 reverses the 
effects of CGG repeat RNA on translation of ARC RNA in hnRNP A2 RNA granules in rat 
neurons and in human fibroblast cells. 
Calcium homeostasis 
Several RNAs encoding proteins associated with calcium homeostasis contain CGG repeats or 
A2REs and thus are likely found in hnRNP A2 RNA granules (8,24). Since translation of these 
RNAs may be regulated by CGG repeats in the same granules, it is important to analyze 
calcium homeostasis as a marker for cellular homeostasis in premutation cells. Cortical 
astrocytes from CGG KI mice exhibit spontaneous asynchronous calcium oscillations (65). 
Futhermore, iPSC-derived fragile X premutation neurons, exhibit calcium transients with 
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increased amplitude and frequency (66). This suggests that calcium signaling and calcium 
homeostasis may be affected by granule RNA translation in premutation cells. We show in 
chapter 2 that premutation human fibroblast cells exhibit secondary calcium transients in 
response to stimulation with Bradykinin. 
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Chapter2: 
CGG repeats in the 5’UTR of FMR1 RNA regulate translation of other 
RNAs localized in the same RNA granules. 
Rovozzo R, Korza G, Baker MW, Li M, Battacharyya A, Barbarese E, et al. (2016) CGG 
Repeats in the 5'UTR of FMR1 RNA Regulate Translation of Other RNAs Localized in the Same 
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Abstract 
CGG repeats in the 5’UTR of Fragile X Mental Retardation 1 (FMR1) RNA mediate RNA 
localization and translation in granules.  Large expansions of CGG repeats (> 200 repeats) in 
FMR1, referred to as full mutations, are associated with fragile X syndrome (FXS).  Smaller 
expansions (55-200 repeats), referred to as premutations, are associated with fragile X tremor 
ataxia syndrome (FXTAS) and fragile X primary ovarian insufficiency (FXPOI). TMPyP4 is a 
porphyrin ring compound that destabilizes CGG repeat RNA secondary structure.  Here we 
show that exogenous CGG repeat RNA by itself, lacking the FMRP ORF, microinjected into 
hippocampal neurons is localized in RNA granules and inhibits translation of ARC RNA, which is 
localized in the same granules. TMPyP4 rescues translation of ARC RNA in granules. We also 
show that in human premutation fibroblasts with endogenous CGG repeat expansions in the 
FMR1 gene, translation of ARC RNA is inhibited and calcium homeostasis is disrupted and both 
phenotypes are rescued by TMPyP4.  Inhibition of granule RNA translation by expanded CGG 
repeats and rescue of granule RNA translation by TMPy4, represent potential pathogenic 
mechanism and therapeutic strategy, respectively, for FXTAS and FXPOI. 
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Introduction 
CGG repeat sequences have been identified in >200 different RNAs in the human exome (1). In 
some cases expansion of CGG repeats is associated with neurological or neuromuscular 
disorders (2).  For example, the Fragile X Mental Retardation 1 (FMR1) gene, encoding fragile X 
mental retardation protein (FMRP), normally contains 5-55 CGG repeats in the 5’UTR. Large 
expansions of CGG repeats (> 200 repeats) in the FMR1 gene, referred to as full mutations, 
cause DNA methylation and transcriptional silencing, resulting in fragile X syndrome (FXS), a 
neurodevelopmental disorder characterized by intellectual disability and autism (3). Smaller 
expansions of CGG repeats (55-200 repeats) in the same gene, referred to as premutations, are 
associated with fragile X tremor ataxia syndrome (FXTAS), a late onset neurodegenerative 
disorder characterized by tremor, ataxia and cognitive decline (4-6) and fragile X primary 
ovarian insufficiency (FXPOI), characterized by infertility and early menopause (7). 
Most eukaryotic RNAs undergo conventional translation, which initiates at an AUG start codon 
at the beginning of the open reading frame (ORF) and terminates at a stop codon at the end of 
the ORF, resulting in synthesis of the protein encoded by the ORF. RNAs such as FMR1, which 
contain trinucleotide repeats in the 5’UTR, can also undergo an unconventional type of 
translation, called repeat associated non-AUG (RAN) translation, which initiates at non-AUG 
sites in the vicinity of the repeats in the 5’UTR, resulting in synthesis of poly-amino acid RAN 
translation products encoded by the repeat sequences (8-11).  Pathogenesis of FXTAS is 
believed to reflect toxicity of either the CGG repeat expansion RNA itself or of RAN translation 
products encoded by CGG repeat expansion RNA, although the mechanism(s) of toxicity are 
unclear.  
CGG repeats can form secondary structures (hairpins, duplexes) by a combination of canonical 
C(anti)::G(anti) and non-canonical G(syn)::G(anti) base pairing (12), which may cause 
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ribosomes to stall in the CGG repeat region of the 5’UTR. Expanded CGG repeats in FMR1 
RNA are associated with reduced translation of the downstream FMRP ORF (13,14), 
suggesting that expanded CGG repeats might increase stalling of ribosomes in the 5’UTR, 
decreasing translation of the downstream ORF. TMPyP4 (tetra-(N-methyl-4-pyridyl) porphyrin) 
is a membrane-permeant porphyrin ring compound that binds to CGG repeat RNA and 
destabilizes RNA secondary structure. TMPyP4 reverses the effect of expanded CGG repeats 
on FMRP translation (13,14), possibly by preventing ribosome stalling in the CGG repeat region. 
Heterogeneous nuclear ribonucleoprotein (hnRNP) A2 binds to CGG repeats, which are found 
in multiple different RNAs, including FMR1 RNA (15-17), and also to A2 response elements 
(A2RE), which are also found in multiple RNAs, including activity regulated cytoskeletal 
associated protein (ARC) RNA (18).  Single molecule imaging reveals that both FMR1 RNA and 
ARC RNA are localized and translated in granules and that newly-synthesized FMRP and ARC 
protein molecules both accumulate in the vicinity of the granule where they are synthesized 
(19). 
Since FMR1 RNA, and ARC RNA, are both localized and translated in the same RNA granules 
(19), and since expanded CGG repeats in FMR1 RNA inhibit translation of FMRP, possibly by 
causing ribosomes to stall in the 5’UTR, the presence of expanded CGG repeat RNA in 
granules might affect conventional translation of ARC RNA localized in the same granules and 
TMPyP4 might block this effect.  In this regard, expression of CGG repeat expansion RNA in 
transgenic mice and flies does affect translation of other RNAs (20).  
Several RNAs containing CGG repeats or A2RE sequences and therefore may be localized in 
the same granules as FMR1 RNA, encode proteins that regulate calcium homeostasis in the cell 
(1,18). Previous work has shown that calcium transients are increased in astrocytes from CGG 
KI mice (21) and in iPSC-derived neurons from individuals with FXTAS (22), both of which 
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contain CGG repeat expansions.  If CGG repeat expansions in FMR1 RNA affect translation of 
these RNAs this could potentially affect calcium homeostasis in the cell.  
Here we show that exogenous CGG repeat RNA, microinjected into neurons and endogenous 
CGG repeat expansions in FMR1 RNA expressed in premutation fibroblasts both inhibit 
translation of ARC RNA, which is localized in the same granules as FMR1 RNA and serves as a 
reporter for translation in granules, and that calcium homeostasis is also affected in premutation 
fibroblasts. Furthermore, TMPyP4 rescues translation of ARC RNA in neurons and in 
premutation fibroblasts and also rescues calcium homeostasis in premutation fibroblasts. 
Materials/Methods 
Ethics statement 
Use of animals as described in this study followed the guidelines of UConn Health and those of 
the National Institutes of Health for the Care and Use of Laboratory Animals, and was approved 
under Protocol # 100686-0416 by the Institutional Animal Care and use Committee (IACUC) of 
UConn Health.  UConn Health complies with all applicable provisions of the Animal Welfare Act 
and other Federal statutes and regulations relating to animals.  UConn Health Animal Welfare 
Assurance number is A3471-01. 
Skin biopsies were obtained from selected patients at the Waisman Center at the University of 
Wisconsin - Madison following recruitment, consent and sample collection procedures approved 
by the University of Wisconsin-Madison Health Sciences Institutional Research Board of the 
Human Research Protection Program (HRPP). Prior to consent and sample collection potential 
subjects were screened in person to determine study eligibility. Subjects found to be eligible 
underwent approved consent procedures, including written informed consent.  Skin biopsies 
were obtained by a physician at the Waisman Center and fibroblasts were isolated from skin 
biopsies. 
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The University of Connecticut Health Institutional Review Board has specifically exempted the 
use of human cell lines (fibroblasts produced at the Waisman Center at the University of 
Wisconsin-Madison and fibroblasts obtained from the Coriell Institute for Medical Research) in 
this study from IRB approval because the cell lines are de-identified. 
CGG repeat profiles 
Profiles of sequential CGG repeats in target sequences were calculated using a sliding 
sequence algorithm that compares a query sequence consisting of four sequential CGG repeats 
to sequential consecutive overlapping 12 nt sequences in the target RNA sequence and 
calculates homology scores at each position.  Perfect homology between the query sequence 
and the target sequence yields a homology score of 1 at that position.  Homology scores < 1 
indicate less than perfect homology.  Multiple sequential CGG repeats in the target sequence 
produce a profile of peaks with homology scores of 1 at positions where the CGG repeats in the 
query and target sequences are aligned, separated by intervening lower scores where the CGG 
repeats in the query and target sequences are misaligned. 
Ribosome profiles 
Ribosome profiling is a technique that reveals the probability of ribosomes localized at each 
position on an RNA molecule (23). In most RNAs, ribosome probability is high in the ORF of the 
RNA, reflecting active translation in this region, and low in the 5’UTR and 3’UTR, indicating less 
active translation in these regions. In RNAs with trinucleotide repeats or upstream ORFs in the 
5’UTR, ribosome probability in the 5’UTR may be increased if translation is increased in these 
regions.  However, ribosome probability in regions of CGG repeats may be underestimated by 
this technique because sequencing through long regions of CGG repeats is inefficient (24).  
Ribosome profiles for FMR1 RNA, representing global aggregate data from multiple published 
studies with multiple different cell types under multiple different conditions (25-35), were 
obtained from the GWIPS-viz database (http://gwips.ucc.ie).  
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In vitro transcription 
ARC RNA and Venus-ARC RNA were prepared by in vitro transcription of linearized plasmid 
DNA, as previously described (18,19). CGG 0, 30, 62 and 99 RNAs were prepared by in vitro 
transcription from plasmid DNA containing FMR1 cDNA with 0, 30, 62 or 99 CGG repeats, 
respectively, obtained from Dr. Fry (13).  Plasmid DNAs were linearized at the Xho 1 site 
immediately downstream of the CGG repeat region.  Labeled RNAs were prepared by in vitro 
transcription in the presence of Cy3- or Cy5-conjugated UTP (all UTPs from GE Healthcare 
Biosciences, Pittsburgh, PA) using T7 mScript Standard mRNA Production System, according 
to manufacturer's protocol (CellScript, Madison, WI) or Amplicap-Max T3 High Yield Message 
Maker Kit (CellScript, Madison, WI) followed by capping and polyadenylation using reagents 
supplied in the T7 mScript Standard mRNA Production System (CellScript, Madison, WI) or 
Amplicap-Max T3 High Yield Message Maker Kit (CellScript, Madison, WI).  Intactness and 
purity of in vitro transcribed RNAs were analyzed by gel electrophoresis and fluorescence 
correlation spectroscopy (FCS). 
Surface plasmon resonance analysis 
Biotin labeled CGG 0, 30, 62 and 99 RNA ligands prepared by in vitro transcription in the 
presence of biotin-UTP, were immobilized on a streptavidin Biacore chip, and binding to serial 
dilutions of TMPyP4 analyte was measured using a Biacore T100 instrument.  Sensorgrams 
were fitted to a heterogeneous ligand model to determine binding parameters for specific and 
non-specific binding of TMPyP4 to each RNA. 
Cell culture, microinjection and confocal imaging 
Hippocampal neurons obtained from C57Bl/6 E19 mouse embryos were grown in culture as 
described previously (18).  Human fibroblasts were obtained from unaffected normal controls 
with normal numbers of CGG repeats in the FMR1 gene and from apparently unaffected female 
premutation carriers with expanded numbers of CGG repeats in the FMR1 gene (see “Human 
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fibroblasts” below).  Fibroblasts were grown in culture as recommended by the Coriell Institute 
cell repository with the addition of α-tocopherol (10 μg/ml) (Sigma Cat# T3251-5G), a lipophilic 
radical scavenger used to reduce cellular autofluorescence in cultured human fibroblast cells 
(36). 
Primary mouse hippocampal neurons (14 to 21 days in culture) or human fibroblasts, grown in 
the presence or absence of 1M TMPyP4 (Calbiochem, Darmstadt, Germany) were 
microinjected using an electronic microinjection system (Eppendorf, Hamburg, Germany).  
Injected cells were identified by fluorescence microscopy. Three channel confocal images of 
injected cells were collected by recording simultaneously in the 488λ, 560λ and 633λ channels 
using a Zeiss LSM 510 confocal laser scanning microscope with a 63X 1.4 numerical aperture 
oil immersion objective lens (Carl Zeiss, Thornwood, NY). Images were collected with maximum 
dynamic range and minimum background in each channel, while avoiding image saturation 
(pixels >255) or image offset below background (pixels <0).  Individual RNA granules were 
masked and fluorescent intensity for each granule was integrated in each channel after 
subtracting background fluorescence using Image J. Specific translational activities were 
calculated by dividing the fluorescence intensity of newly-synthesized Venus-ARC protein, 
measured in the 488λ channel, by the fluorescence intensity of Venus-ARC RNA, measured in 
the 633λ channel.  
Fluorescence Correlation Spectroscopy (FCS) photobleaching 
The numbers of fluorescent RNA molecules in individual granules were determined by FCS 
(37,38). Counts per molecule for Cy5-conjugated-UTP-labelled CGG 99 RNA and Alexafluor 
488-conjugated-UTP-labelled ARC RNA were first determined by FCS in solution. Both RNAs 
were co-injected into primary mouse hippocampal neurons in culture.  Dual channel confocal 
images of injected cells were collected to visualize individual granules containing both 
fluorophores.  The FCS observation volume was positioned to encompass a single RNA granule 
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and FCS counts were recorded for 10 s, during which the count rate decayed due to 
photobleaching of fluorescent RNA molecules in the granule, which is immobile.  The numbers 
of fluorescent RNA molecules of each type in each granule were determined by subtracting 
counts remaining after 10 s from counts at time 0 and dividing by counts per molecule. 
Calcium transients 
Fibroblasts in culture were loaded with Fluo-4 calcium indicator, according to the manufacturer’s 
protocol (Life Technologies).  Bradykinin was bath applied to the cells to induce calcium 
transients.  Fluo-4 fluorescence was recorded by time lapse confocal microscopy after 
bradykinin addition. Fluo-4 fluorescence in individual cells was quantified by masking each cell 
and integrating total fluorescence in the cell at each time step.  Calcium transients were 
expressed as ΔF/F0. 
Human fibroblasts 
Fibroblasts were isolated from skin biopsies obtained from selected patients at the Waisman 
Center at the University of Wisconsin-Madison per Institutional Review Board–approved human 
subject protocols. The following fibroblast lines were analyzed:  FX08-01 (full mutation), FX08-
02 (premutation), FX11-01 (full mutation), FX11-02 (premutation), FX13-01 (full mutation), 
FX13-02 (premutation), WC26 (double premutation), C0603 (control). In addition GM00497 
(control) and GM00498 (control) fibroblasts from apparently unaffected individuals were 
purchased from the Coriell Cell Repository. 
In the case of FX08-02, FX11-02, FX13-02 and C0603 cell lines the numbers of FMR1 CGG 
repeats were determined using a PCR-based protocol previously described (39). The protocol 
combines gene-specific primers that flank the CGG repeat region of the FMR1 gene with 
gender-specific primers, a polymerase mixture, and a reaction buffer optimized for amplification 
of GC rich DNA. PCR was performed on an ABI Veriti thermal cycler (Applied Biosystems, 
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Grand Island, NY).  CGG repeat numbers were determined by agarose gel electrophoresis of 
PCR products and confirmed by capillary electrophoresis on an ABI 3730xl DNA Analyzer with 
POP-7 195 polymer using a 50-cm array (40), which is capable of defining exact CGG repeat 
number on samples with 200 CGG repeats or less.  
In the case of WC26 and C0603 a different, previously described assay was used to determine 
the FMR1 CGG repeats (41). Amplification of CGG repeats and flanking sequences was 
performed with AccuPrime Pfx DNA Polymerase (Thermo Fisher Scientific) in 15 ul reactions 
containing 0.15 ul of Pfx polymerase, 1x Reaction Mix, 2.5 M Betaine (Sigma), 7.5% DMSO 
(Sigma), 50 ng of genomic DNA, and 0.3 uM of each primer CGG-F 
(TCAGGCGCTCAGCTCCGTTTCGGTTTCA) and CGG-R 
(AAGCGCCATTGGAGCCCCGCACTTCC). Samples were amplified with an initial denaturation 
step of 98°C for 5 min; 35 cycles of 98°C for 35 s, 64°C for 35 s, and 68°C for 2 min, and a final 
extension step at 68°C for 5 min. PCR products were resolved on agarose gel electrophoresis. 
The CGG repeat number was estimated by comparing to DNA sizing ladder visualized on 
agarose gel electrophoresis. 
Western blotting 
Expression of FMRP in fibroblast cell lines was analyzed by Western blotting with antibody to 
FMRP as described previously (42,43). 
Results 
CGG repeat and ribosome profiles for FMR1 RNA 
Figure 1 shows CGG repeat profiles and ribosome profiles for exon 1 of FMR1 RNA, which 
includes the 5’UTR and initial portion of the ORF.  The CGG profile reveals a region of CGG 
repeats between positions 100-150 in the 5’UTR of FMR1 RNA. The ribosome profile reveals 
regions of increased ribosomal density between position 200-250, presumably reflecting  
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Figure 1: CGG repeat profile and ribosome profile for FMR1 RNA. Panel A shows the CGG 
profile for exon 1 of FMR1 RNA, including the 5’UTR (blue) and the initial portion the ORF (red), 
calculated as described in Materials and Methods. There is a region of CGG repeats between 
positions 100-150, interrupted by a single AGG at position 131.  Panel B shows the 
corresponding ribosome profile for exon 1 of FMR1 RNA. The number of sequence reads at 
each position reflects the probability of ribosomes located at that position. Increased ribosome 
probability downstream of position 200 presumably reflects ribosomes engaged in conventional 
translation of the FMRP ORF beginning at the AUG at position 230.  Increased ribosome 
probability in upstream regions (1-100 and 150-200) may reflect ribosomes initiating translation 
at non-canonical AUG-like sites upstream of the CGG repeats or ribosomes engaged in RAN 
translation of 5’UTR CGG repeats, consistent with reports that translation of CGG repeats in 
FMR1 RNA may require non-canonical AUG-like sequences upstream of the CGG repeats (11).  
The paucity of reads in the region between 100-150, which corresponds to the CGG repeat 
region, may reflect inefficient sequencing through long regions of CGG repeats (24).    Panel C 
shows the ribosome profile for the entire FMR1 gene (red) and the locations of individual exons 
(blue), with 5’ and 3’UTR regions indicated by thinner lines and ORF regions indicated by 
thicker lines.  The exon 1 region shown in panels A and B is indicated. 
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ribosomes engaged in conventional translation of the FMR1 ORF and between positions 0-125, 
which may reflect ribosomes stalled in the CGG repeat region in the 5’UTR of FMR1. The 
number of sequence reads in the CGG repeat region may underestimate the actual ribosome 
density in this region because sequencing through long sequences of CGG repeats is inefficient 
(24).  For comparison, the ribosome profile and exon locations for the entire FMR1 gene are 
shown in Fig. 1C.  Ribosome densities for most exons are comparable, indicating that 
translational activity is relatively uniform across the ORF.  Ribosome density in the 5’UTR is 
slightly lower compared to ribosome density in the ORF, indicating that RAN translation activity 
in the CGG repeat region is slightly lower than conventional translational activity in the ORF.  
Expansion of CGG repeats in the 5’UTR of FMR1 RNA in premutation cells could potentially 
further increase ribosome density in this region.  This has not been tested directly because 
ribosome profiling has not been performed with premutation cells.       
TMPyP4, is a membrane-permeant tetraporphyrin ring compound that binds to, and disrupts, 
CGG repeat RNA secondary structure (13,14). TMPyP4 binding to CGG repeat RNA was 
characterized by surface plasmon resonance (SPR) analysis with CGG repeat RNA as ligand 
and TMPyP4 as analyte, as shown in Fig. 2. CGG repeat profiles for RNA transcripts derived 
from FMR1 RNAs with 0, 30, 62 and 99 CGG repeats are shown in panels A-D. In each 
transcript the 5’ flanking region from position 1-101 in FMR1 RNA, corresponding to the region 
with increased ribosome density in Fig. 1, is identical, followed by different numbers of CGG 
repeats (0, 30, 62, 99) for each transcript.  To compare the TMPyP4 binding parameters for 
nonCGG repeat regions and for CGG repeat regions, SPR sensorgrams for TMPyP4 binding to 
RNAs with 0, 30, 62 and 99 repeats (shown in panel E) were globally fitted to a heterogeneous 
ligand binding model to determine non-specific and specific binding parameters for each 
transcript (shown in panel F).  One set of binding parameters is similar for all transcripts (KD ~  
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Figure 2: CGG repeat profiles and TMPyP4 binding for FMR1, CGG0, CGG30, CGG62 and 
CGG99 RNAs. Panels A-D - CGG repeat profiles for RNAs derived from the 5’UTR of FMR1 
RNAs containing CGG 0, 30, 62, 99 were calculated using a sliding sequence algorithm 
(described in Materials Methods). Values of 1 in the profile indicate four consecutive CGG 
repeats in a row. Panel E – Binding of each CGG repeat RNA to serial dilutions of TMPyP4 was 
analyzed by SPR.  Panel E shows representative SPR sensorgrams for binding of TMPyP4 to 
CGG 0, 30, 62 and 99 RNAs.  Panel F – On-rates and off-rates determined by fitting SPR 
sensorgrams for each RNA to a heterogeneous ligand binding model.  Apparent KD values were 
calculated by dividing off rates by on rates   NSp indicates non-specific binding, Sp indicates 
CGG-specific binding for each RNA. 
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0.5 μM), presumably corresponding to non-specific binding of TMPyP4 to common nonCGG 
repeat regions present in each transcript.  In addition, CGG 30, 62 and 99 RNAs, exhibit a 
second set of binding parameters, presumably corresponding to specific binding of TMPyP4 to 
different number of CGG repeats in each transcript. Apparent on-rates for CGG-specific binding 
are similar for CGG 30, 62 and 99 RNAs (ka ~ 2 x 104 M-1s-1) but apparent off-rates are slower 
for CGG99 RNA (kd ~ 2 x 10-6 s-1) compared to CGG30 and CGG62 RNAs (kd ~ 2 x 10-4 s-1).  
This may reflect tighter binding of TMPyP4 to CGG 99 RNA compared to CGG 30 and CGG 62 
RNAs, possibly because of increased numbers of CGG repeats, or alternatively, may reflect 
rebinding of TMPyP4 to CGG99 RNA during the dissociation phase. In any case, these results 
indicate that TMPyP4 binds non-specifically to nonCGG repeat sequences and specifically to 
CGG repeat sequences.  Overall the apparent KD for TMPyP4 binding to all RNAs is < 1 μM.  
Accordingly, in subsequent experiments, cells were incubated with TMPyP4 at a final 
concentration of 1 μM to ensure saturation binding to all CGG repeat RNA molecules in the cell.  
CGG repeat RNA molecules and Venus-ARC RNA molecules are co-localized in granules 
and CGG repeat RNA inhibits translation of Venus-ARC RNA in the same granule. 
FMR1 RNA containing CGG repeats is localized and translated in RNA granules (19). To 
determine if CGG repeats by themselves are sufficient for RNA localization in granules and if 
CGG repeat RNA affects translation of other RNAs localized in the same granules, CGG0 and 
CGG99 RNAs were microinjected into hippocampal neurons, along with Venus-ARC RNA, as a 
marker for granules and as a reporter for granule RNA translation. CGG0 and CGG99 RNAs 
were labelled by in vitro transcription with Cy3-UTP and Venus-ARC RNA was differentially 
labeled by in vitro transcription with Cy5-UTP.  Co-injected neurons were incubated for 2 hours 
to allow time for localization and translation of the injected RNAs in individual granules.  
Fluorescent Venus-ARC RNA, fluorescent CGG repeat RNA and fluorescent newly synthesized 
Venus-ARC protein were imaged simultaneously by three channel confocal microscopy. The 
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relative amounts of each component associated with each granule were quantified by 
integrating fluorescent intensities in each channel for each granule.  In some experiments 
neurons were incubated with TMPyP4, prior to microinjection, to disrupt secondary structure in 
CGG repeat RNA.  The experimental protocol is outlined schematically in Fig. 3A. 
The experimental protocol outlined Fig. 3A is based on several considerations.  Hippocampal 
neurons were used to analyze localization and translation in granules because individual 
granules are well resolved in neuronal dendrites. Venus-ARC RNA was used as a marker for 
granules because it contains an A2RE sequence that binds to hnRNP A2 and mediates 
localization in granules (18). It also serves as a reporter for translation in granules because 
Venus-ARC RNA is translated in granules and newly-synthesized Venus-ARC protein 
molecules remain in the vicinity of the granule where they are synthesized (19).  Truncated 
CGG repeat RNAs derived from the 5’UTR of FMR1 RNA but lacking the FMRP ORF, were 
injected to test the effect of CGG repeat RNA itself, without potential confounding effects of 
FMRP protein. CGG0 and CGG99 RNAs were used because they do not represent substrates 
for conventional translation, since they lack initiation and termination codons, although the 
region upstream of the CGG repeats in FMR1 does contain several non-canonical AUG-like 
sequences that could potentially mediate translation initiation at low efficiency (11).  Because 
CGG99 contains CGG repeats it is localized in granules and may represent a substrate for RAN 
translation. CGG repeats can also form secondary structures, which may cause ribosomes to 
stall in the vicinity of the CGG repeats.  Fluorescent RNAs were injected directly into the 
cytoplasm rather than into the nucleus in order to assay effects of CGG repeat RNA on 
cytoplasmic translation, while avoiding effects of CGG repeats on nuclear processes, such as 
nuclear inclusion formation (44), nuclear processing or nuclear transport that could potentially 
affect subsequent translation or decay in cytoplasm.  There are several reasons to believe that 
CGG repeat RNA is not degraded during the course of the experiment.   Eukaryotic cells have  
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Figure 3: CGG repeat RNA and ARC RNA are co-localized in granules and CGG repeat 
RNA inhibits translation of ARC RNA in hippocampal neurons. Panel A shows a schematic 
outline of the experimental protocol.  Differentially labeled CGG repeat RNA and Venus-ARC 
RNA were co-injected into the cytoplasm of hippocampal neurons where they are localized in 
granules in dendrites.  Venus-ARC RNA is translated in granules near dendritic spines.  In some 
cases hippocampal neurons were incubated with membrane-permeant TMPyP4 before injecting 
RNA. Panel B shows the distribution of Venus-ARC RNA (red), CGG99 RNA (blue) and newly-
synthesized Venus-ARC protein (green) in discrete granules in a three channel confocal images 
of a dendritic segment. Seven granules are visible in this dendritic segment, all of which contain 
Venus-ARC RNA, two of which also contain CGG99 RNA, and five of which lack detectable 
CGG99 RNA. Newly synthesized Venus-ARC protein is detected in the five granules lacking 
CGG99 RNA but not in the two granules containing CGG99 RNA.  Scale bar indicates 1 m. 
Panel C shows 3-dimensional graphs of fluorescence intensities for Venus-ARC RNA, Venus-
ARC protein and CGG99 (right panel) or CGG0 (left panel) RNAs in a population of individual 
granules in hippocampal neurons. Panel D shows Kolmogorov-Smirnov cumulative frequency 
plots of specific translational activities (Venus-ARC protein/Venus-ARC RNA) for granules 
containing detectable CGG99 RNA (red), defined as integrated fluorescence intensity > 10 
arbitrary units, or in granules where CGG99 RNA was undetectable (black), defined as 
integrated fluorescence intensity < 10 arbitrary units.  Specific translational activities were 
measured for granules in untreated (left panel) or in TMPyP4-treated (right panel) hippocampal 
neurons. 
 
 
 
 
 
 
 
 
 
 
  
43 
multiple different decay pathways for degrading dysfunctional RNAs including: nonsense 
mediated decay (NMD), triggered by premature nonsense codons in the RNA (45), non-stop 
decay (NSD), triggered by lack of a termination codon preceding the polyA tail on the RNA (46), 
and no-go decay (NGD), triggered by stalled elongation on the RNA (47). CGG repeat RNAs do 
not represent substrates for NMD, because they lack termination codons or for NSD, because 
they lack a polyA tail. CGG repeat RNAs could potentially represent substrates for NGD, if 
translation elongation is stalled by CGG repeat secondary structure in the injected RNA.  
However injection of fluorescent RNA into the cytoplasm provides an internal control for RNA 
degradation because fluorescent fragments produced by RNA decay in the cytoplasm are 
translocated to the nucleus (18).  In this experiment none of the injected cells showed 
detectable nuclear fluorescence, indicating that RNA injected into the cytoplasm was not 
degraded during the time of the experiment.   RNA localization and translation in granules were 
measured 2 hours after microinjection in order to analyze primary effects of CGG repeat RNA 
on granule RNA translation, while minimizing potential secondary effects due to RNA toxicity, 
decay or changes in cellular physiology caused by long term presence of exogenous CGG 
repeat RNA in the cell.   
Fig. 3B shows several individual granules in a representative dendritic segment from a 
microinjected neuron and Fig. 3C shows total integrated fluorescence intensities for 
microinjected Venus-ARC RNA, CGG99 RNA (right panel) or CGG0 RNA (left panel) and 
newly-synthesized Venus-ARC protein in multiple individual granules. Venus-ARC RNA is 
detected in all RNA granules, CGG99 RNA is detected in a subset of Venus-ARC RNA granules 
and Venus-ARC protein is detected in granules that do not contain detectable CGG99 RNA but 
not in granules that contain detectable CGG99 RNA, indicating that CGG repeat RNA inhibits 
translation of Venus-ARC RNA localized in the same granule. Microinjected CGG0 RNA is not 
detected in granules and does not affect synthesis of Venus-ARC protein in granules.  These 
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results indicate that CGG repeat RNA is localized in granules and inhibits translation of Venus-
ARC RNA in the same granules. 
To quantify specific translational activities in individual granules, Venus-ARC RNA and newly-
synthesized Venus ARC protein were measured in multiple granules, with and without 
detectable CGG99 RNA (Fig. 3, panels C and D).  Specific translational activities were 
calculated by dividing the amount of newly-synthesized Venus-ARC protein by the amount of 
Venus-ARC RNA in each granule.  Individual granules exhibit variable translational activities, 
which is consistent with previous single molecule imaging observations of translational output 
from individual granules (19).  In order to compare translational activities for a large population 
of granules the results are presented in the form of a Kolmogorov-Smirnov plot showing 
cumulative frequencies for granules with different specific translational activities.  Granules 
without detectable CGG99 RNA (black symbols) exhibit a range of translational activities (0.01 -
50), with a small proportion (~10%) of translationally inactive granules.  Variation in translational 
activity among granules without exogenous CGG99 RNA may be due to variable amounts of 
endogenous CGG repeat RNAs in different granules.  Granules with detectable CGG99 RNA 
(red symbols) exhibit reduced translational activities (0.01 - 5) with a larger proportion (~40%) of 
translationally inactive granules.  This indicates that CGG99 RNA localized in granules inhibits 
translational activity of Venus-ARC RNA localized in the same granules. 
TMPyP4, binds to CGG repeat RNA and disrupts CGG repeat secondary structure. To 
determine if TMPyP4 rescues granule RNA translation, neurons were treated with TMPyP4 prior 
to injection with Cy5-labeled Venus-ARC RNA, by itself or with CGG99 RNA (Fig. 3D).  In 
TMPyP4–treated cells, the ranges of translational activities in individual granules, with 
detectable CGG99 RNA (red symbols) or without detectable CGG99 RNA (black symbols), are 
similar (the cumulative frequency plots are superimposable) and translationally inactive granules 
are not detected in either case. Since TMPyP4 binds specifically to CGG repeats and since 
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Venus-ARC RNA does not contain CGG repeats, and since TMPyP4 differentially affects 
translation of granules containing CGG repeat RNA, the effect of TMPyP4 on translation of 
Venus-ARC RNA may be mediated by its binding to CGG repeat RNA molecules in the same 
granules.  These results indicate that TMPyP4 rescues translation of Venus-ARC RNA in 
granules containing CGG99 RNA.   
If CGG repeat RNA inhibits translation of other RNAs in the same granule, the magnitude of 
inhibition may reflect the number of CGG repeat RNA molecules relative to other RNA 
molecules in the same granule.  The numbers of CGG repeat RNA and ARC RNA molecules in 
individual granules were determined by fluorescence correlation spectroscopy (FCS) 
photobleaching (Fig. 4) (37,38).  Alexafluor 488-labeled ARC RNA and Cy5-labeled CGG99 
RNA were first analyzed by FCS in solution to determine fluorescence counts per molecule for 
each RNA. For these experiments ARC RNA was used instead of Venus-ARC RNA in order to 
avoid fluorescence from newly-synthesized Venus-ARC protein. The numbers of Alexafluor 488-
ARC RNA and Cy5-CGG99 RNA molecules in individual granules in live cells were determined 
by positioning the FCS volume to encompass a single immobile RNA granule and recording 
decay of counts over time in each channel due to photobleaching of fluorescent RNA molecules 
in the immobile granule during the FCS measurement.  Dividing the total loss of counts per 
granule by counts per individual RNA molecule provides a measure of the number of RNA 
molecules of each type in the granule encompassed by the FCS volume (Fig. 4A).  Endogenous 
CGG repeat or A2RE RNA molecules in individual granules are not detected by FCS 
photobleaching because they are not fluorescent.    
In the absence of TMPyP4 (Fig. 4B), the relative numbers of ARC RNA molecules and CGG99 
RNA molecules per granule are correlated over the population of granules but the absolute 
number of CG99 RNA molecules is greater than the number of ARC RNA molecules in most 
granules.  This suggests that CGG99 RNA molecules and ARC RNA molecules are assembled  
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Figure 4: FCS photobleaching of ARC RNA and CGG 99 RNA molecules in individual 
granules in hippocampal neurons. Panel A – the FCS observation volume was positioned to 
encompass a single individual immobile granule containing differentially labeled fluorescent 
ARC RNA and CGG99 RNA molecules in a hippocampal neuron.  Continuous illumination 
during the FCS measurement results in photobleaching of fluorescent RNA molecules of each 
type in the granule, which is recorded as count rate decay in each FCS channel.  The numbers 
of fluorescent RNA molecules of each type in the granule are determined by dividing the total 
decay in counts during photobleaching by the counts per molecule for each RNA determined by 
FCS in solution. Panel B shows a scatter plot for numbers of ARC RNA and CGG99 RNA 
molecules in individual granules in hippocampal neurons in the absence of TMPyP4. Panel C 
shows a scatter plot for numbers of ARC RNA and CGG99 RNA molecules in individual 
granules in hippocampal neurons in the presence of TMPyP4. Panel D shows Kolmogorov-
Smirnov plots of the ratios of CGG99 RNA molecules to ARC RNA molecules in individual 
granules in the absence (black symbols) and presence (red symbols) of TMPyP4.  
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into granules by similar mechanisms but CGG 99 RNA is assembled more efficiently than ARC 
RNA.  In the presence of TMPyp4 (Fig. 4C) the number of CGG99 RNA molecules compared to 
ARC RNA molecules is slightly increased.  Fig. 4D shows the ratios of CGG99 RNA molecules 
to ARC RNA molecules for granules in the absence and presence of TMPyP4.  In the absence 
of TMPyP4 the ratio varies from 1-10, indicating that CGG99 RNA molecules are assembled 
into granules more efficiently than ARC RNA molecules. CGG99 RNA contains multiple CGG 
repeat sequences that can potentially bind to multiple hnRNP A2 molecules, which may mediate 
more efficient assembly into granules, while ARC RNA contains a single A2RE sequence that 
binds to a single hnRNP A2 molecule, which may mediate less efficient assembly into granules. 
In the presence of TMPyP4 the ratios are shifted slightly to higher values indicating that 
assembly of CGG99 RNA molecules into granules is slightly enhanced.  Disruption of secondary 
structure by TMPyP4 may increase binding of hnRNP A2 molecules to CGG repeat RNA 
molecules, which could facilitate more efficient assembly into RNA granules.  This could result 
in increased hnRNP A2 concentration in CGG99 RNA granules in the presence of TMPyP4 but 
this was not tested experimentally.   
In the absence of TMPyP4 the range of values for the ratio of CGG99 RNA to ARC RNA in 
individual granules (1-10) is narrower than the range of values for translational activities in 
CGG99 containing granules (compare Fig. 4B to Fig. 3D).  This indicates that inhibition of 
granule RNA translation by CGG repeat RNA is not linearly proportional to the ratio of CGG99 
RNA and ARC RNA in individual granules.  This non-linearity could be due to CGG repeat RNA 
affecting translation of other endogenous RNAs that encode proteins known to regulate 
translation [1].  If CGG99 RNA inhibits translation of such endogenous RNAs this could amplify 
the effect of CGG99 RNA on translation of ARC RNA in granules.  
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CGG repeat expansions in endogenous FMR1 RNA inhibit translation of Venus-ARC RNA 
in premutation human fibroblasts. 
The effect of CGG repeat expansions in endogenous FMR1 RNA on translation of Venus-ARC 
RNA was analyzed by microinjecting Venus-ARC RNA labeled with Cy5-UTP into human 
fibroblasts from premutation carrier individuals with different numbers of CGG repeats in the 
endogenous FMR1 gene (Fig. 5). Microinjected Venus-ARC RNA and newly-synthesized 
Venus-ARC protein were imaged in multiple cells by dual channel confocal microscopy two 
hours after injection to allow time for injected RNA to be translated.  Fluorescent Venus-ARC 
RNA was restricted to the cytoplasm and appeared to have a granular distribution, suggesting 
that the injected RNA was localized in granules and was not degraded (Fig. 5A).  However in 
most cells discrete individual granules were not sufficiently well resolved from each other to 
quantify RNA in individual granules. Newly-synthesized Venus-ARC protein accumulates in both 
cytoplasm and nucleus of fibroblasts, as reported previously (48).   
Total fluorescent RNA and total fluorescent protein were integrated over the entire cell as a 
measure of the total amount of injected Venus-RNA and the total amount of newly-synthesized 
Venus-ARC protein, respectively, in each cell.  Specific translational activities were calculated 
by dividing the amount of Venus-ARC protein by the amount of Venus-ARC RNA in each cell. 
The results for multiple individual cells from 3 control and 4 premutation fibroblast cell lines are 
shown in cumulative Kolmogorov-Smirnov plots (Fig. 5B).  In control fibroblasts (C0603, 
GM00497, GM00498) from individuals with normal numbers of CGG repeats in the FMR1 gene, 
most cells exhibit translational activities between 1-10.  Intrinsic variation in control cells may be 
due to cell-to-cell variations in expression of other endogenous CGG repeat RNAs that affect 
translation in these cells. In premutation fibroblasts (FX08-2, FX11-2, FX13-2) from individuals 
with CGG repeat expansions in one copy of the FMR1 gene, some cells exhibit translational 
activities comparable to control cells (1-10) while other cells exhibit reduced translational 
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Figure 5: CGG repeat expansions in the FMR1 gene inhibit translation of Venus-ARC RNA 
in human fibroblasts. Panel A - Human fibroblasts from control individuals C0603 (control 
male, 31 repeats), GM00497 (control male, unknown repeat number), GM00498 (control male, 
unknown repeat number) and FMR1 premutation carriers FX08-2 (female, 31, 105 repeats), 
FX11-2 (female, 20, 79 repeats), FX13-2 (female, 33, 85 repeats), and WC26 (female, two 
premutation alleles, 60, 90 repeats) were microinjected with Venus-ARC RNA and after 2 hours 
Venus-ARC RNA and newly-synthesized Venus-ARC protein were imaged by dual channel 
confocal microscopy.  Representative images are shown for untreated control and premutation 
cells and for premutation cells treated with TMPyP4.  Scale bars indicate 5m. Panel B – 
Cumulative Kolmogorov Smirnov plots for specific translational activities (newly-synthesized 
Venus-ARC protein/microinjected Venus-ARC RNA) in individual cells for 3 control and 4 
premutation fibroblast cell lines as described for Panel A, untreated (top) and treated with 
TMPyP4 (bottom). Panel C – Frequency distribution plots for specific translational activities 
(newly-synthesized Venus-ARC protein/microinjected Venus-ARC RNA) in cells for 3 control 
and 4 premutation fibroblast cell lines as described for Panel B, untreated (top) and treated with 
TMPyP4 (bottom). Panel D – PCR analysis of CGG repeat numbers in FX08-02, FX11-02, 
FX13-02 and C0603 fibroblasts with a 100 bp DNA ladder (left panel) and in WC26 and C0603 
fibroblasts with a 1 Kb ladder  (right panel).  In the panel on the left, in the FX08-2, FX11-2, and 
FX13-2 lanes, the band at the bottom of the gel represents female gender specific PCR product, 
the bands immediately above the gender specific band represent PCR products from CGG 
repeat alleles in the normal range and the bands above represent PCR products from expanded 
CGG repeat alleles.  The fainter products near the top of the gel are of unknown origin.  In the 
C0603 lane, the two bands near the bottom of the gel represent male and female gender 
specific PCR products, and the band the gender specific bands represents PCR product from 
the normal CGG repeat allele.  In the panel on right, the two bands in the WC26 lane both 
represent PCR products from expanded CGG repeat alleles and the single band in the C0603 
lane represents PCR product from the CGG repeat allele in the normal range. Panel E – Table 
showing ID, gender, FMR1 alleles and CGG repeat numbers (based on panel D) for each cell 
line. Panel F – Western blotting of FMRP expression in full mutation (FX08-1, FX11-01, FX13-
01) and premutation (FX08-2, FX11-02 and FX13-02) cell lines with actin loading controls.    
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activities (0.02-1). The translational activities in the second sub-population exhibit the same rank 
order as the number of CGG repeats in the expanded FMR1 allele in the different cell lines 
(FX08>FX13>FX11), suggesting that inhibition of translational activity is proportional to CGG 
repeat number in different cell lines.  In cells from one individual with CGG repeat expansions in 
both FMR1 alleles (WC26), specific translational activities are reduced in all cells. 
To determine if TMPyP4 rescues translation in premutation fibroblasts, cells were treated with 
TMPyP4 for 24 hours prior to injection with Venus-ARC RNA.  After TMPyP4 treatment, control 
and premutation fibroblasts exhibit comparable specific translational activities, which are similar 
to untreated control cells.  This indicates that TMPyP4 rescues translation in premutation 
fibroblasts from individuals with CGG repeat expansions in the endogenous FMR1 gene, which 
is consistent with the effect of TMPyP4 on granule RNA translation in neurons microinjected 
with exogenous CGG repeat RNA.  These results indicate that translation of Venus-ARC in 
human fibroblasts is inhibited by CGG repeat expansions in FMR1 RNA and rescued by 
TMPyP4. 
The existence of two subpopulations of cells with different translational activities could reflect 
random X inactivation of different FMR1 alleles in different sub-populations of fibroblasts.  In 
cells with reduced translational activities, the FMR1 allele with expanded CGG repeats may be 
active, while in cells with normal translational activities, the FMR1 allele with normal CGG 
repeat numbers may be active.  In WC26 cells, with reduced translational activities in all cells, 
either FMR1 allele may be active because both alleles contain CGG repeat expansions.  To test 
this possibility, translational activities in different cell lines were plotted as a frequency 
distribution plot (Fig. 5C).  Control cells (C0603, GM00497, GM00498) with a single FMR1 allele 
with normal numbers of CGG repeats, exhibit a unimodal distribution with normal translational 
activities.  Premutation cells (FX08-2, FX11-2, FX13-2) with one normal and one FMR1 allele 
with expanded CGG repeats exhibit a bimodal distribution of translational activities (one normal 
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and one reduced) and the double premutation cells (WC26) with expanded CGG repeats in both 
FMR1 alleles, exhibit a unimodal  distribution with reduced translational activities in all cells.   In 
cells treated with TMPyP4 all cell lines exhibit unimodal distributions with normal translational 
activities.  These results indicate that in premutation carrier cells with one normal FMR1 allele 
and one premutation FMR1 allele with expanded CGG repeats, translational activity is 
determined by the active FMR1 allele in each cell. 
FMRP is a translational repressor that inhibits ARC translation.  Levels of FMRP expression are 
generally not affected much in premutation cells (42,43). However, variation in Venus-ARC 
translation in different premutation fibroblast cell lines could conceivably reflect variation in 
endogenous FMRP expression in these specific lines. Western blotting showed comparable 
levels of FMRP expression in FX08-2, FX11-2 and FX13-2 cell lines (Fig. 5F). This analysis 
would not necessarily detect variations of FMRP expression due to X-inactivation of different 
FMR1 alleles in different subpopulations of cells. Since expanded CGG repeats in FMR1 RNA 
may reduce expression of FMRP from the downstream ORF, subpopulations of cells where the 
FMR1 allele with expanded CGG repeats is active might have reduced FMRP expression, which 
would be expected to result in increased ARC translation. However the results show decreased 
ARC translation in these cells.  Moreover, TMPyP4 increases FMRP expression from FMR1 
RNA with expanded CGG repeats, which might decrease ARC translation. However the results 
show increased ARC translation in the presence of TMPyP4. For these reasons it is unlikely that 
variation in Venus-ARC translation in different cell lines is primarily due to variations in FMRP 
expression. 
CGG repeat expansions in the FMR1 gene cause increased calcium transients in human 
fibroblasts. 
Expanded CGG repeats in endogenous FMR1 RNA inhibit translation of Venus-ARC RNA, 
which is a reporter for translation of RNAs localized in the same granules as FMR1 RNA.   
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Translation of endogenous RNAs localized in the same granules may also be inhibited, which 
may result in additional cellular phenotypes. In this regard, previous studies have shown that 
calcium transients are increased in astrocytes from CGG KI mice, which contain a CGG repeat 
transgene (21), and in iPSC-derived neurons from individuals with expanded CGG repeats in 
the endogenous FMR1 gene (22).  These observations suggest that expanded CGG repeat 
RNA inhibits translation of endogenous RNAs encoding proteins that mediate calcium 
homeostasis. To determine if calcium transients are affected in fibroblasts from individuals with 
CGG repeat expansions in the endogenous FMR1 gene, control and premutation human 
fibroblasts were loaded with Fluo-4 as a calcium indicator and bradykinin was added to induce 
calcium transients (Fig. 6).  Fluo-4 fluorescence in individual cells was imaged by time lapse 
confocal microscopy.  Calcium transients were detected by integrating Fluo-4 fluorescence over 
each cell at each time point.   In control fibroblasts (C0603), bradykinin induced a single primary 
calcium transient, which returned to baseline after ~ 20 sec in all cells.  In premutation 
fibroblasts with expanded CGG repeats in the endogenous FMR1 gene (FX08-2), the primary 
calcium transient was followed by secondary calcium transients in some cells.  The time interval 
between primary and secondary calcium transients was variable (20-60 sec) among different 
cells.  These results indicate that CGG repeat expansions in the endogenous FMR1 gene 
disrupt calcium homeostasis in premutation fibroblasts.  Premutation cells that did not exhibit 
secondary calcium transients may represent cells in which the normal FMR1 allele is active and 
the allele with expanded CGG repeats is inactivated. 
To determine if TMPyP4 rescues calcium homeostasis in premutation fibroblasts, cells were 
treated with TMPyP4 for 24 hours before analyzing bradykinin-induced calcium transients.  In 
TMPyP4-treated control and premutation fibroblasts, bradykinin induced a single primary 
calcium transient with no secondary transients.  This indicates that TMPyP4 rescues calcium  
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Figure 6: CGG repeat expansions in the FMR1 gene disrupt regulation of calcium 
transients in human fibroblasts. Control (C0603) and premutation (FX08, 31,105 repeats) 
fibroblasts were loaded with fluorescent calcium indicator Fluo-4 and incubated with bradykinin 
to induce calcium transients.  Cells were imaged by time-lapse confocal microscopy to visualize 
changes in intracellular calcium concentrations over time. Total fluorescence intensity over the 
entire cell was integrated in each time frame for 20 control and 20 premutation cells, in the 
absence or presence of TMPyP4.  F/F0 values for each cell are plotted, with initiation of primary 
calcium transients aligned at time = 0 s. 
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homeostasis in premutation fibroblasts and that CGG repeat expansions in the endogenous 
FMR1 gene are associated with a phenotype that is manifested in fibroblasts. 
The control fibroblasts used in these experiments were obtained from apparently normal male 
individuals with normal numbers of CGG repeats in the FMR1 gene, while the premutation 
fibroblasts were obtained from apparently normal female individuals carrying premutation CGG 
expansions in the FMR1 gene.  This raises the possibility that the observed differences in 
granule RNA translation and calcium homeostasis between control and premutation fibroblasts 
could reflect gender differences rather than differences in CGG repeat expansions in the FMR1 
gene.  We believe this possibility is unlikely for several reasons. First, in cells with one normal 
FMR1 allele and one premutation allele, some cells exhibit normal granule RNA translation and 
calcium homeostasis, while others exhibit reduced granule RNA translation and disrupted 
calcium homeostasis, while in cells where both FMR1 alleles contain CGG repeat expansions, 
all cells exhibit reduced granule RNA translation. Since the FMR1 gene is located on the X 
chromosome, which is subject to random X inactivation in different cells, this suggests that 
granule RNA translation and calcium homeostasis are regulated by the number of CGG repeats 
in the active FMR1 allele in each cell, rather than by the gender of the donor.  Second, the 
extent of inhibition of granule RNA translation in premutation cells is proportional to the number 
of CGG repeats in the premutation allele of the FMR1 gene, suggesting that granule RNA 
translation is regulated by the number of CGG repeats in the FMR1 gene rather than by gender 
differences.  Third, both translation and calcium homeostasis in premutation cells are rescued 
by TMPyP4, which binds to CGG repeat RNA and destabilizes CGG repeat secondary 
structure, suggesting that both translation and calcium homeostasis are regulated by CGG 
repeats rather than by gender differences.  For these reasons we believe the differences in 
granule RNA translation and calcium transients between control and premutation human 
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fibroblasts observed in this study are likely due to differences in CGG repeat number in the 
endogenous FMR1 gene rather than to gender differences.  
Discussion 
CGG repeat RNAs, such as FMR1 RNA, and A2RE RNAs, such as Venus-ARC RNA, are 
localized and translated in the same RNA granules.  CGG repeat RNA inhibits translation of 
ARC RNA in the same granule and TMPyP4 rescues ARC RNA translation in granules 
containing CGG repeat RNA.  These observations can be explained by multiple potential 
mechanisms involving component(s) in granules that: 1) regulate translation; 2) are affected by 
CGG repeats; and 3) whose effects are reversed by TMPyP4. Here we will discuss three 
potential mechanisms involving components that meet these criteria: hnRNP A2, ribosomes, 
and EIF2AK2. 
The first potential mechanism involves hnRNP A2, which binds to CGG repeat RNA (15-17) and 
is known to enhance translation of A2RE RNAs in granules (49).  If RNA molecules with 
expanded CGG repeats bind increased numbers of hnRNP A2 molecules this could potentially 
reduce the number of hnRNP A2 molecules available to bind to ARC RNA molecules, which 
could potentially reduce translation of ARC RNA in granules.  Several considerations argue 
against this possibility.  First, the concentration of hnRNP A2 in cytoplasm is quite high (6 M), 
which suggests that this component may not be rate limiting for translation of ARC RNA.  
Second, since hnRNP A2 is required for assembly of ARC RNA into granules, reduced binding 
of hnRNP A2 to ARC RNA might result in reduced assembly of ARC RNA into granules, which 
was not observed (Fig. 4). Third, TMPyP4 rescues translation but is not known to interact with 
hnRNP A2.  For these reasons it seems unlikely that intragranule competition between CGG 
repeat RNA and A2RE RNA for hnRNP A2 is responsible for inhibition of ARC RNA translation 
by CGG repeat RNA in the same granule. 
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The second mechanism involves ribosomes, which are required for translation of ARC RNA and 
also accumulate in the vicinity of CGG repeats.  Ribosome profiling reveals increased ribosome 
density in the vicinity of CGG repeats in the 5’UTR of FMR1. If the number of CGG repeats is 
expanded, the ribosome density in this region could be further increased, although this has not 
been tested experimentally.  Increased ribosome density in the CGG repeat region might reduce 
the number of ribosomes available for translation of ARC RNA in the same granule.  The 
magnitude of such an effect would depend on the relative number of ribosomes associated with 
expanded CGG repeats in the 5’UTR of premutation FMR1 RNA molecules compared to the 
total number of ribosomes in each granule.  In this regard, single molecule imaging reveals that 
granules with increased numbers of RNA molecules do not have increased numbers of 
translational events per granule (19), which implies that the number of ribosomes per granule 
may be rate limiting for translation. Furthermore, if secondary structure in CGG repeat RNA 
causes ribosomes to accumulate in the 5’UTR of FMR1 RNA, TMPyP4 might reduce ribosome 
density by disrupting CGG repeat secondary structure in this region, which might increase 
availability of ribosomes for translation of ARC RNA in the same granules, reversing the effects 
of CGG repeat expansion.  These considerations are consistent with intragranule competition 
between CGG repeat RNA and ARC RNA for ribosomes as a potential mechanism for inhibition 
of ARC RNA translation by CGG repeat RNA in the same granule. 
The third mechanism involves EIF2AK2, eukaryotic translation initiation factor 2 alpha kinase 2, 
a serine/threonine protein kinase activated by dsRNA that inhibits conventional translation by 
phosphorylating translation initiation factor EIF2a (50).   EIF2AK2 RNA itself contains CGG 
repeats in the 5’UTR (1), which may mediate localization and translation of EIF2AK2 RNA in the 
same granules as FMR1 RNA and ARC RNA.  CGG repeats in FMR1 RNA can form dsRNA 
secondary structure, which may activate EIF2AK2, thereby inhibiting ARC RNA translation in 
the same granule.  Expansion of CGG repeats in FMR1 RNA may increase stability of dsRNA 
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secondary structure, thereby increasing activation of EIF2AK2 and reducing translation of ARC 
RNA.   TMPyP4 may destabilize CGG repeat dsRNA secondary structure in FMR1 RNA, 
thereby reversing activation of EIF2AK2 and rescuing translation of ARC RNA.  These 
considerations are consistent with activation of EIF2AK2 by CGG repeat RNA as a potential 
mechanism for inhibition of ARC RNA translation in the same granule.  
The above, and other, potential mechanisms could be distinguished by knocking out or inhibiting 
specific components that are: localized in the same granules as FMR1 RNA, regulate translation 
of other RNAs in the same granule, are potentially affected by CGG repeat expansions in FMR1 
RNA, and whose effects are potentially reversed by TMPyP4.  However, without such 
experimental validation it is not possible to identify specific components that account for the 
observations reported here.    
The human exome contains multiple different CGG repeat RNAs besides FMR1 RNA and 
multiple different A2RE RNAs besides ARC RNA, some of which may be localized in the same 
RNA granules as FMR1 RNA because CGG repeat sequences and A2RE sequences both bind 
to hnRNP A2, which mediates granule assembly. This may create an intra-granule translational 
regulatory network, where expansion of CGG repeats in one RNA increases the overall CGG 
repeat burden in the granule, thereby decreasing translation of other RNAs in the same granule. 
Since CGG repeat RNAs and A2RE RNAs encode multiple different proteins that mediate 
multiple different cellular functions, regulating translation of these RNAs in granules could have 
pleiotropic effects on the cell.  In this regard, expression of a CGG repeat transgene is known to 
affect translation of multiple different RNAs in mice and flies (20), which could explain why 
expansions of CGG repeats in various genes are associated with pleiotropic pathological 
manifestations such as: late onset, tremors, ataxia, dysphagia (difficulty swallowing), dysarthria 
(difficulty speaking).    
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Calcium homeostasis is a complex cellular process mediated by multiple different proteins, 
some of which are encoded by CGG repeat and/or A2RE RNAs.  For example: CGG repeat 
RNAs such as: CACNA1A (voltage dependent calcium channel) and KCNMA1 (calcium 
activated potassium channel), could potentially affect calcium homeostasis and A2RE RNAs 
such as CAMK2A (calcium, calmodulin-dependent protein kinase 2A) and NRGN 
(neurogranin/calmodulin binding protein) could also potentially affect calcium homeostasis. If 
calcium homeostasis is mediated by proteins encoded by CGG repeat and/or A2RE RNAs that 
are localized in granules and translationally regulated by CGG repeat RNA this could explain 
why calcium homeostasis is disrupted in premutation fibroblasts from individuals with CGG 
repeat expansions in the endogenous FMR1 gene.  However it is difficult to identify one specific 
gene or group of genes that mediates the calcium phenotype in premutation fibroblasts to 
because multiple different CGG repeat and/or A2RE RNAs encode proteins could potentially 
affect calcium homeostasis and TMPyP4 can potentially affect multiple different pathways in the 
cell. 
TMPyP4 binds to CGG repeat RNA and rescues granule RNA translation and calcium 
homeostasis. The effect of TMPyP4 on calcium homeostasis may be secondary to the effect on 
granule RNA translation if translation of RNAs that mediate calcium homeostasis is inhibited by 
CGG repeat RNA and rescued by TMPyP4. However, it is also possible that TMPyP4 affects 
calcium homeostasis directly.  Previous studies have shown that TMPyP4 can induce calcium 
release by direct interaction with the Ca2+ release protein from sarcoplasmic reticulum (51).  
Furthermore, studies in yeast suggest that TMPyP4 can induce a cellular oxidative stress 
response that could affect calcium homeostasis (52).  TMPyP4 rescue of translation and 
calcium homeostasis in premutation fibroblasts could theoretically involve similar mechanisms.    
The observation that granule RNA translation and calcium homeostasis are dysregulated in 
premutation fibroblasts indicates that pathogenic effects of CGG repeat expansions in FMR1 
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(and possibly other CGG repeat genes) are manifested in non-neuronal cell types. In this study 
premutation fibroblasts that exhibit dysregulated granule RNA translation and calcium 
homeostasis were obtained from apparently healthy young female premutation carriers with no 
apparent neurological or neuromuscular symptoms. This indicates that disrupted granule RNA 
translation and calcium homeostasis in human fibroblasts may provide early preclinical 
biomarkers for identifying individuals at increased risk to develop late onset neurological or 
neuromuscular disorders such as FXTAS, FXPOI or other CGG repeat disorders. Chronic, 
sustained disruption of granule RNA translation and/or calcium homeostasis may be deleterious 
to the cell over the long term and may contribute to late onset development of neurological or 
neuromuscular pathology in these individuals. Restoring normal granule RNA translation and/or 
calcium homeostasis with TMPyP4 could potentially reduce the risk of subsequent onset of 
these disorders in premutation carriers.  Inhibition of translation in granules by CGG repeat 
expansions in FMR1 RNA represents a potential pathogenic mechanism for CGG repeat 
expansion disorders such as FXTAS and FXPOI.  Rescue of translation in granules by TMPyP4 
could potentially ameliorate pathogenic effects in CGG repeat expansion disorders. 
My contributions to this work 
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63 
References 
1. Kozlowski P, de Mezer M, Krzyzosiak WJ. Trinucleotide repeats in human genome and 
exome. Nucleic Acids Res. 2010; 38(12):4027-39. 
 
2. McMurray CT. Mechanisms of trinucleotide repeat instability during human development. Nat 
Rev Genet. 2010; 11(11):786-99. 
 
3. Bassell GJ, Warren ST. Fragile X syndrome: loss of local mRNA regulation alters synaptic 
development and function. Neuron 2008; 60: 201–214. 
 
4. Garcia-Arocena D, Hagerman PJ.  Advances in understanding the molecular basis of FXTAS. 
Hum Mol Genet. 2010; 19(R1):R83-9. 
 
5. Kenneson, A, Zhang, F, Hagedorn, CH, Warren ST. Reduced FMRP and increased FMR1 
transcription is proportionally associated with CGG repeat number in intermediate-length and 
premutation carriers. Hum Mol Genet. 2001; 10:1449-1454. 
 
6. Todd PK Oh SY, Krans A, He F, Sellier C, Frazer M, Renoux AJ, Chen KC, Scaglione KM, 
Basrur V, Elenitoba-Johnson K, Vonsattel JP, Louis ED, Sutton MA, Taylor JP, Mills RE, 
Charlet-Berguerand N,Paulson HL. CGG repeat-associated translation mediates 
neurodegeneration in fragile X tremor ataxia syndrome. Neuron 2013; 78(3):440-55. 
 
7. Sullivan SD, Welt C, Sherman S. FMR1 and the continuum of primary ovarian insufficiency. 
Semin Reprod Med. 2011; 29(4):299-307. 
 
8. Zu T, Gibbens B, Doty NS, Gomes-Pereira M, Huguet A, Stone MD, Margolis J, Peterson M, 
Markowski TW, Ingram MAC, Nan Z, Forester C, Low WC, Schoser B, Somia N, Clark HB, 
Schmechel S, Bitterman PB, Gourdon G, Swanson MS, Moseley M, Ranum LPW. Non-ATG-
initiated translation directed by microsatellite expansions. Proc Natl Acad Sci USA. 2010; 
108(1): 260-265. 
 
9. Cleary JD, Ranum LP. Repeat-associated non-ATG (RAN) translation in neurological 
disease. Hum Mol Genet. 1013; 22(R1)R45-51. doi: 10.1093/hmg/ddt371 PMID: 23918658 
 
10. Cleary JD, Ranum LP. Repeat associated non-ATG (RAN) translation: new starts in 
microsatellite expansion disorders. Curr Opin Genet Dev. 2014; 26C:6-15. 
 
11. Kearse MG, Green KM, Krans A, Rodriguez CM, Linsalata AE, Goldstrohm AC, Todd PK. 
CGG repeat-associated non-AUG translation utilizes a cap-dependent scanning mechanism of 
initiation to produce toxic proteins. Mol Cell 2016; 62(2):314-22. 
 
  
64 
12. Kiliszek A, Kierzek R, Krzyosiak WJ, Rypniewski W. Crystal structures of CGG RNA repeats 
with implications for fragile X-associated tremor ataxia syndrome. Nucleic acids Res. 2011; 
39(16):7308-7315. 
 
13. Ofer, N, Weisman-Shomer, P, Shklover, J, Fry M. The quadruplex r(CGG)n destabilizing 
cationic porphyrin TMPyP4 cooperates with hnRNPs to increase the translation efficiency of 
fragile X premutation mRNA. Nucl Acids Res. 2009; 37:2712-2722. 
 
14. Morris MJ, Wingate KL, Silwal J, Leeper TC, Basu S. The porphyrin TmPyP4 unfolds the 
extremely stable G-quadruplex in MT3-MMP mRNA and alleviates its repressive effect to 
enhance translation in eukaryotic cells. Nucl Acids Res. 2012; 40:4137-4145. 
 
15. Muslimov IA, Patel MV, Rose A, Tiedge H. Spatial code recognition in neuronal RNA 
targeting: Role of RNA-hnRNP A2 interactions. J Cell Biol. 2011 Aug 8; 194(3): 441-457. PMCID: 
PMC3153643 
 
16. Sofola OA, Jin P, Qin Y, Duan R, Liu H, de Haro M, Nelson DL, Botas J. RNA-binding 
proteins hnRNPA2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced 
neurodegeneration in a Drosophila model of FXTAS. Neuron 2007; 55(4):565-71. 
 
17. Jin P, Duan R, Qurashi A, Qin Y, Tian D, Rosser TC, Liu H, Feng Y, Warren ST. Pur alpha 
binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a Drosophila model 
of fragile X tremor/ataxia syndrome. Neuron 2007; 55(4):556-64. 
 
18. Gao Y, Tatavarty V, Korza G, Levin MK, Carson JH. Multiplexed dendritic targeting of {alpha} 
calcium calmodulin-dependent protein kinase II, neurogranin, and activity-regulated cytoskeleton-
associated protein RNAs by the A2 pathway. Mol Biol Cell. 2008; 19:2311-27. 
 
19. Tatavarty V, Ifrim MF, Levin M, Korza G, Barbarese E, Yu J, Carson JH. Single molecule 
imaging of translational output from individual RNA granules in neurons. Mol Biol Cell. 2012; 
23(5):918-29. 
 
20. Galloway JN, Shaw C, Yu P, Parghi D, Poidevin M, Jin P, Nelson DL. CGG repeats in RNA 
modulate expression of TDP-43 in mouse and fly models of fragile X tremor ataxia syndrome. 
Hum Mol Genet. 2014 Nov; 23(22):5906-5915. Doi: 10.1093/hmg/ddu314. PMID: 24986919 
 
21. Cao Z, Hulsizer S, Cui Y, Pretto DL, Kim KH, Hagerman PJ, Tassone F, Pessah IN. 
Enhanced asynchronous Ca(2+) oscillations associated with impaired glutamate transport in 
cortical astrocytes expressing Fmr1 gene premutation expansion. J Biol Chem. 2013; 
288(19):13831-41. 
 
  
65 
22. Liu J, Koscielska KA, Cao Z, Hulsizer S, Grace N, Mitchell G, Nacey C, Githinji J, McGee J, 
Garcia-Arocena D, Hagerman RJ, Nolta J, Pessah IN, Hagerman PJ. Signaling defects in iPSC-
derived fragile X premutation neurons. Hum Mol Genet. 2012; 21(17):3795-805. 
 
23. Ingolia NT, Ghaemmaghami S, Newman JR, Weissman JS. Genome-wide analysis in vivo of 
translation with nucleotide resolution using ribosome profiling. Science. 2009; 324(5924):218-23. 
 
24. Loomis EW, Eid JS, Peluso P, Yin J, Hickey L, Rank D, McCalmon S, Hagerman RJ, 
Tassone F, Hagerman PJ. Sequencing the unsequencable – expanded CGG repeats of the 
fragile X gene. Genome Res. 2013; 23(1):121-8. 
 
25. Battle A, Khan Z, Wang SH, Mitrano A, Ford MJ, Pritchard JK, Gilad Y. Genomic variation. 
Impact of regulatory variation from RNA to protein. Science. 2015; 347(6222):664-7. 
 
26. Cenik C, Cenik ES, Byeon GW, Grubert F, Candille SI, Spacek D, Alsallakh B, Tilgner H, 
Araya CL, Tang H, Ricci E, Snyder MP. Integrative analysis of RNA, translation, and protein 
levels reveals distinct regulatory variation across humans. Genome Res. 2015; 25(11):1610-21. 
 
27. Elkon R, Loayza-Puch F, Korkmaz G, Lopes R, van Breugel PC, Bleijerveld OB, Altelaar AF, 
Wolf E, Lorenzin F, Eilers M, Agami R. Myc coordinates transcription and translation to enhance 
transformation and suppress invasiveness. EMBO Rep. 2015; 16(12):1723-36. 
 
28. Iwasaki S, Floor SN, Ingolia NT. Rocaglates convert DEAD-box protein eIF4A into a 
sequence-selective translational repressor. Nature 2015; 534, 558–561. 
 
29. Jang C, Lahens NF, Hogenesch JB, Sehgal A. Ribosome profiling reveals an important role 
for translational control in circadian gene expression. Genome Res. 2015; 25: 1836-1847. 
 
30. Reid DW, Shenolikar S, Nicchitta CV. Simple and inexpensive ribosome profiling analysis of 
mRNA translation. RNA-based methods in virology 2015; 91: 69–74. 
 
31. Tanenbaum ME, Stern-Ginossar N, Weissman JS, Vale RD. Regulation of mRNA translation 
during mitosis eLife 2015; 4:e07957. 
 
32. Tirosh O, Cohen Y, Shitrit A, Shani O, Le-Trilling VTK, Trilling M, Friedlander G, Tanenbaum 
MT. The Transcription and Translation Landscapes during Human Cytomegalovirus Infection 
Reveal Novel Host-Pathogen Interactions. PloS Pathog. 2015;  24;11(11):e1005288. 
 
33. Sidrauski C, McGeachy AM, Ingolia NT, Walter P. The small molecule ISRIB reverses the 
effects of eIF2α phosphorylation on translation and stress granule assembly. eLife 2015; 
4:e05033. 
 
  
66 
34. Werner A, Iwasaki S, McGourty CA, Medina-Ruiz S, Teerikorpi N, Fedrigo I, Ingolia NT, Rape 
M. Cell-fate determination by ubiquitin-dependent regulation of translation. Nature 2015; 525, 
523–527. 
 
35. Wiita AP, Ziv E, Wiita PJ, Urisman A, Julien O, Burlingame AL, Weissman JS, Wells JA. 
Global cellular response to chemotherapy-induced apoptosis. eLife 2013; 2:e01236. 
 
36. Poot M, Visser WJ, Verkerk A, Jongkind JF. Autofluorescence of human skin fibroblasts 
during growth inhibition and in vitro ageing. Gerontology 1985; 31(3):158-65. 
 
37. Levin MK, Carson JH. Fluorescence correlation spectroscopy and quantitative cell biology. 
Differentiation 2004; 72:1-10. 
 
38. Paradise A, Levin MK, Korza G, Carson JH. Significant proportions of nuclear transport 
proteins with reduced intracellular mobilities resolved by fluorescence correlation spectroscopy. J 
Mol Biol. 2007; 365(1):50-65. 
 
39. Seltzer MM, MW Baker, J Hong, M Maenner, J Greenberg. Mandel D. Prevalence of CGG 
expansions of the FMR1 gene in a US population-based sample. Am J Med Genet B 
Neuropsychiatr Genet. 2012; 159B:589–597. 
 
40. Miramon H, Cavelier F, Martinez J, Cottet H. Highly resolutive separations of hardly soluble 
synthetic polypeptides by capillary electrophoresis. Anal Chem.  2010; 82(1):394-9. 
 
41. Filipovic-Sadic S, Sah S, Chen L, Krosting J, Sekinger E, Zhang W, Hagerman PJ, Stenzel 
TT, Hadd AG, Latham, GJ, Tassone F. A novel FMR1 PCR method for the routine detection of 
low abundance expanded alleles and full mutations in fragile X syndrome. Clin Chem 2010; 
56(3):399-408. 
 
42. Devys D, Lutz Y, Rouyer N, Bellocq JP, and Mandel JL. The FMR-1 protein is cytoplasmic, 
most abundant in neurons and appears normal in carriers of a fragile X premutation. Nature 
genetics. 1993 Aug; 4(4):335-340. 
 
43. Tassone F, Hagerman RJ, Taylor AK, Mills JB, Harris SW, Gane LW, and Hagerman PJ. 
Clinical involvement and protein expression in individuals with the FMR1 premutation. American J 
Med Genet. 2000 March; 91(2):144-152. 
 
44. Tassone F, Iwahashi C, Hageman PJ. FMR1 RNA within the intranuclear inclusions of Fragile 
X-associated tremor/ataxia syndrome (FXTAS). RNA Biology 2004; 1:2, 103-105. 
 
45. Chang YF, Imam JS, Wilkinson MF. The nonsense-mediated decay RNA surveillance 
pathway. Annu Rev Biochem.  2007; 76:51-74. 
  
67 
46. Vasudevan S, Peltz SW, Wilusz, CJ. Non-stop decay--a new mRNA surveillance pathway. 
BioEssays 2002; 24 (9): 785–8. 
 
47. Harigaya Y, Parker R. No-go decay: a quality control mechanism for RNA in translation. Wiley 
Interdiscipl Rev RNA 2010; 1(1):132-41. 
 
48. Korb E, Wilkinson CL, Delgado RN, Lovero KL, Finkbeiner S.  Arc in the nucleus regulates 
PML-dependent GluA1 transcription and homeostatic plasticity. Nat Neurosci. 2013; 16(7):874-
83. 
 
49. Kwon S, Barbarese E, Carson JH. The cis-acting RNA trafficking signal from myelin basic 
protein mRNA and its cognate trans-acting ligand hnRNP A2 enhance cap-dependent translation. 
J Cell Biol. 1999; 147(2):247-56. 
 
50. Barber GN, Wambach M, Wong ML, Dever TE, Hinnebusch AG, Katze MG. Translational 
regulation by the interferon-induced double-stranded-RNA-activated 68-kDa protein kinase. Proc 
Natl Acad Sci USA. 1993 May; 90(10):4621–4625. 
 
51. Abramson JJ, Milne S, Buck E, Pessah IN. Porphyrin induced calcium release from skeletal 
muscle sarcoplasmic reticulum. Arch Biochem Biophys. 1993; 301(2):396-403. 
 
52. Andrew EJ, Merchan S, Lawless C, Banks AP, Wilkinson DJ, Lydall D. Pentose phosphate 
pathway function affects tolerance to the G-quadruplex binder TMPyP4. PLOS One 8(6): e66242. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
68 
Chapter3: 
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Abstract 
An expanded CGG repeat tract in the 5’UTR of the FMR1 gene is associated with the fragile X 
family of disorders, including smaller expansions (~55-200), referred to as premutation 
expansions, associated with fragile X tremor ataxia syndrome (FXTAS) and fragile X primary 
ovarian insufficiency (FXPOI) and larger expansions (>200), referred to as full mutation 
expansions, associated with fragile X syndrome (FXS). One current controversy in the field 
centers on whether the premutation disorders are RNA gain of function disorders or 
protein/peptide gain of function disorders. Here we show that exogenous CGG repeat RNA (not 
in the context of FMR1) microinjected into mouse oocytes inhibits translation of VenusArc, a 
reporter hnRNP A2 granule RNA, but a transgenic construct containing 90 CGG repeats, a 
small part of the FMR1 open reading frame and part of intron 1, does not inhibit VenusArc RNA 
microinjected into transgenic TG296 mouse oocytes. By comparison to experiments in chapter 2 
with Venus Arc coinjected with synthetic CGG repeat RNA and Venus Arc microinjected into 
human fibroblast cells from carriers for the premutation, we show that translational inhibition is 
likely an RNA gain of function mechanism. Furthermore, we show that PKR activation may be 
the mechanism for translational inhibition.  
Introduction 
The fragile X family of disorders is associated with the expansion of a CGG repeat tract in the 
5’UTR of the FMR1 gene located on the X chromosome. In unaffected individuals, the number 
of CGG repeats is less than ~55 repeats. When the number of CGG repeats expands to 
between 55 and 200 CGG repeats, this is referred to as the premutation. Premutation 
expansions are often associated with fragile X tremor ataxia syndrome (FXTAS), a late onset 
neurodegenerative disorder, or fragile X primary ovarian insufficiency (FXPOI). Expansion to 
more than ~200 CGG repeats, called the full mutation, is associated with fragile X syndrome 
(FXS), an early onset mental retardation (1). Experiments in chapter 2 show that exogenous 
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CGG repeat expansion RNA inhibits translation in RNA granules in neurons, which may 
represent a mechanism for FXTAS, which affects neuronal function. Experiments in chapter 2 
also show that CGG repeat expansions in the endogenous FMR1 gene inhibit translation in 
RNA granules in fibroblasts from females at risk for FXPOI (2), which may represent a 
mechanism for FXPOI. In chapter 3, we will investigate whether expanded CGG repeats affect 
translation in RNA granules in mouse oocytes and whether this may represent a potential 
mechanism for FXPOI. 
Primary ovarian insufficiency (POI) is a disorder characterized by infertility, irregular menses 
and early menopause (3).The corresponding reduced estrogen levels result in a number of 
deleterious side effects, including increased rates of twinning, hot flashes, vaginal dryness, 
insomnia, decreased bone mineral density and reduced overall cardiovascular health (4, 5). 
Even more serious is the increased risk for disorders that accompany early menopause, 
including increased risk of coronary heart disease and osteoporosis (6).  FXPOI comprises 4-
6% of all cases of POI (6). In females, up to 24% of premutation carriers present with FXPOI (7, 
8).  
In FXS, the full mutation expansion results in hypermethylation of the DNA resulting in silencing 
of the transcript (9). As a result, this is considered a protein loss of function disorder. However, 
the FMR1 gene is not silenced in the premutation, so FXTAS and FXPOI are not considered 
protein loss of function disorders. The current controversy in the field concerns whether these 
disorders result from protein gain of function or RNA gain of function (10). Chapter 3 will provide 
some insight into which of these mechanisms causes FXTAS and FXPOI. 
The ribosome profile for FMR1 RNA (shown in Figure 1 Chapter 2) reveals increased ribosome 
density in the ORF, presumably representing ribosomes engaged in conventional translation of 
the ORF. Additionally, ribosome density is also increased in the 5’UTR suggesting that 
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ribosomes are stalled in the CGG repeat region (2). This may be indicative of an unconventional 
type of translation called repeat associated nonAUG translation (RAN translation)  RAN 
translation products may be toxic to the cell, which would represent a protein gain of function 
mechanism.  Alternatively, increased ribosome density in the 5’UTR of FMR1 RNA may be due 
to ribosomal stalling at CGG repeat secondary structure in this region (as suggested in chapter 
2), which would represent an RNA gain of function mechanism for FXTAS and FXPOI. 
In chapter 2 exogenous CGG repeat RNA, not in the context of FMR1 RNA, was microinjected 
into mouse hippocampal neurons. 99 CGG repeats were sufficient to co-localize CGG repeat 
RNA in the same granules as VenusArc RNA, a reporter A2RE RNA (2). This verifies that CGG 
repeats are a localization signal, similar to an A2RE, and since A2RE RNAs localize to hnRNP 
A2 RNA granules (11), we can assume CGG repeat RNA localizes to hnRNP A2 RNA granules 
as well. In chapter 3, we will show that hnRNP A2 appears to be granular in oocytes, suggesting 
that hnRNP A2 RNA granules are present in oocytes, which would allow the mechanism for 
RNA toxicity seen in mouse neurons and human fibroblast cells to be recapitulated in mouse 
oocytes. 
Also in chapter 2 we show that the microinjected exogenous CGG99 RNA inhibits translation of 
VenusArc RNA in granules, but granule RNA translation is rescued by TMPyP4, which binds to 
CGG repeat RNA (2) and destabilizes secondary structure (12). This suggests that CGG repeat 
secondary structure is necessary for translational inhibition. In chapter 3 three different potential 
mechanisms are discussed to explain CGG repeat RNA inhibition of translation in RNA 
granules. The first potential mechanism, competition of expanded CGG repeat RNA with other 
granule RNAs for hnRNP A2, is not likely because the concentration of hnRNP A2 in the 
cytoplasm is believed to be in excess (2). The second potential mechanism, sequestration of 
translational machinery by CGG repeat RNA, and the third potential mechanism, activation of 
PKR by CGG repeat RNA, both represent RNA gain of function mechanisms. In chapter 3, we 
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will show that microinjected CGG99 RNA inhibits translation of VenusArc RNA in oocytes, and 
we will discuss the different possible RNA gain of function mechanisms for this affect. 
In chapter 2, we showed that CGG repeat expansions in endogenous FMR1 RNA inhibit 
translation in RNA granules in human fibroblast cells (2). This suggests that the CGG repeat 
microinjection experiment is a good model for FXTAS and FXPOI. In this chapter we explore 
translational inhibition in oocytes as it relates to FXPOI. However, it is difficult to obtain oocytes 
from human subjects, especially in a disease model. Therefore, we investigated the effects of 
exogenous CGG repeat RNA on granule RNA translation in control mouse oocytes and the 
effects of transgenic CGG repeat RNA in transgenic mouse oocytes. The transgenic mouse 
available to us contains a construct with 90 CGG repeats in the 5’UTR of FMR1, part of the 
open reading frame and part of intron 1, making it slightly different from a model with CGG 
repeat expansions in the context of a complete FMR1 RNA ORF (13). In chapter 3, we show 
that endogenous transgenic CGG repeat RNA does not inhibit translation of VenusArc RNA in 
transgenic oocytes. Possible reasons for the different results in FXPOI human fibroblasts and 
transgenic mouse oocytes will be discussed.  
In addition to potential RNA gain of function mechanisms, it is possible that RAN translation 
products of the FMR1 gene with premutation CGG repeats are somehow toxic to the cell 
causing FXTAS or FXPOI by a protein gain of function mechanism (14). In chapter 3, we will 
demonstrate that this is likely not the case. 
Materials/Methods 
CGG repeat profiles 
A sliding sequence algorithm was used to generate CGG repeat homology profiles for the 
various constructs as described in chapter 2 (2). 
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Western blotting 
For Western blots, oocytes were boiled in 1X sample buffer (Laemmli et al) and proteins were 
separated on 4-20% gradient gels (BioRad) and electrophoretically transferred to nitrocellulose 
membranes.   
FMRP 
Membranes were blocked for at least 30 minutes in blocking buffer (TBST + 1% nonfat milk), 
then incubated overnight in primary antibody. FMRP antibody, obtained from Abcam (cat 
#ab17722), was diluted 1:2500 in blocking buffer (TBST+2%milk). Blots were washed in TBST, 
and incubated for at least 60 minutes in secondary antibody.  Secondary antibody obtained from 
Santa Cruz Biotechnology (cat #sc-2004) was diluted 1:5,000 in blocking buffer.  Blots were 
developed using ECLPrime (Life Technologies). 
PKR 
Membranes were blocked for 45min in blocking buffer (4% Bovine Serum Albumin in Tris/NaCl, 
0.2% Tween, pH7.7 (Blotto buffer)) then incubated overnight in primary antibody. PKR antibody, 
obtained from Abcam, was diluted 1:2000 in Blotto buffer. Blots were washed in 8 to 10mL 
Blotto buffer at room temperature for a total of three times and incubated in secondary antibody 
for 1hr at room temperature. Secondary antibody (goat anti-rabbit HRP) obtained from Millipore 
was diluted 1:10,000 in Blotto buffer. Membranes were washed with 8 to 10 mL Blotto buffer for 
10min at room temperature a total of three times, then rinsed with approx. 10ml water five times. 
After the final rinse blots were incubated with 15 mL Tris/NaCL 0.1%Tween, pH7.6 for 15 
minutes. The buffer was discarded and 8 mL ECL reagent (Pierce Super Signal West Pico 
Chemiluminescent Substrate; #34078) was added for 10 minutes. 
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Mice 
Female NSA(CF1) mice were obtained from Harlan Laboratories. Transgenic mice carrying a 
yeast artificial chromosome with the human FMR1 5’UTR containing 90 CGG repeats (13) were 
obtained from Peng Jin (Emory University). These mice were genotyped from ear punches to 
determine that they were positive for the transgene using the REDExtract-N-AmpTissue PCR 
Kit from Sigma and primer sets 5’-TCAAATTGCGAAGGAGCAG-3’ (forward) and 5’-
AACGAATATGTGTTGAGGACCC-3’ (reverse). Males testing positive for the transgene were 
mated with wild type females of the same strain (FVB) to generate transgenic and wild type 
mice. In some cases, female FVB/J mice were obtained from Charles River. FMR1 KO mice 
were obtained from Elisa Barbarese (UConn Health). All experimental protocols involving mice 
were performed with prior approval of the Animal Care and Use Committee at UConn Health. 
Media and Reagents 
Except where noted, all reagents were from Sigma Aldrich (St. Louis, MO). The medium for 
oocyte collection was MEMα (Life Technologies, Carlsbad, CA) supplemented with 20mM 
HEPES (Life Technologies), 75 µg/mL penicillin G, 50 µg/mL streptomycin, 0.1% polyvinyl 
alcohol (PVA), and 10µM milrinone to inhibit spontaneous meiotic resumption. For overnight 
culture, oocytes were placed in bicarbonate-buffered MEMα, in which the HEPES was replaced 
with 25mM sodium bicarbonate. 
Collection and culture of oocytes 
Fully grown germinal vesicle (GV)-stage oocytes were obtained from the ovaries of >6 wk-old 
mice primed 42-46 hrs previously with 5 IU pregnant mare serum gonadotropin (PMSG). For 
experiments utilizing TG296 mice, oocytes were obtained from ovaries of 8-9 wk-old mice that 
were not primed with PMSG. Cumulus cells were removed by repeated pipetting through a 
small-bore pipet. Oocytes were cultured in 200 µL drops of medium under light mineral oil on a 
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warming tray set to 37°C (when in HEPES-buffered medium) or in a humidified atmosphere at 
37°C with 5% CO2, 95% air (when in bicarbonate-buffered medium). 
RNA preparation 
Venus DNA was a gift from Dr. Ji Yu (UConn Health, Farmington, CT). Venus-ARC construct 
was derived from ARC cDNA clone (pBS II (SK+) r ARC obtained from Dr. Paul Worley (Johns 
Hopkins University, Baltimore, MD). The ARC open reading frame (ORF) was inserted in-frame 
at the C-terminus of the Venus ORF in a Venus vector. The NotI-NdeI fragment from this clone, 
including the Venus ORF and the first 16 bases from ARC ORF, was excised and religated with 
the corresponding NotI-NdeI fragment of the original ARC cDNA construct. The final construct 
carries the complete ARC ORF and 3′-UTR but not the 5′-UTR. Venus-Arc RNA was prepared 
by in vitro transcription of linearized plasmid DNA as previously described (15, 16). CGG99 
RNA was prepared from plasmid DNA containing FMR1 cDNA with 99 CGG repeats obtained 
from Dr. Fry (12). Plasmid DNA was linearized with XhoI (New England Biolabs) immediately 
downstream of the CGG repeat region followed by use of a MinElute reaction cleanup kit 
(Qiagen) according to the manufacturer’s protocol. In vitro transcription was performed in the 
presence of Cy5-labelled UTP. All UTPs were obtained from GE Healthcare Biosciences, 
Pittsburgh, PA. In vitro transcription of CGG99 RNA was performed using T7 mScript Standard 
Standard mRNA Production System (CellScript, Madison, WI) according to manufacturer’s 
protocol. In vitro transcription of VenusArc RNA  and Venus RNA was performed using 
Amplicap-Max T3 High Yield Message Maker Kit (CellScript, Madison, WI) followed by capping 
and polyadenylation using reagents from the T7 mScript Standard mRNA Production System. 
RNA quality and purity was analyzed by gel electrophoresis and FCS. 
Microinjection 
Quantitative microinjection was performed as described previously (17), using a direct pressure 
system in which a small volume of mercury in a micropipette permits controlled injection of 
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picoliter quantities. Concentrations of injected substances were calculated based on an oocyte 
volume of 200 pL. GFP vector with a CMV promoter was obtained from Clontech. Oocytes that 
were injected with Venus-Arc ± CGG99 RNA were cultured overnight to allow protein 
expression and then were fixed for 1 hr in 2% formaldehyde in 100mM HEPES, 50mM EGTA, 
10mM MgSO4, and 0.2% Triton X-100 at 37°C 23-24 hrs following injection, washed into PBS 
containing 0.1% PVA, and stored at 4°C until imaging. 
Confocal microscopy 
Fluorescent images were acquired using a Zeiss LSM 510 inverted confocal-laser scanning 
microscope with a 40X 1.2 numerical aperture water immersion objective lens at zoom 2 with a 
line average of 8. Multi-channel acquisition was used to scan Venus and Cy5 in channel 1 by 
excitation with a 488nm argon laser and a 633nm HeNe laser followed by scanning of Cy3 in 
channel 2 by excitation with a 561 nm laser. Images without Cy3 were acquired using one 
channel. GFP was imaged with the same properties as Venus in one channel. The emitted light 
was collected in a bandwidth of 500-550nm for Venus and GFP, 650-710nm for Cy5 and 575-
615nm for Cy3.  Differential interference contrast (DIC) images were also collected in channel 1. 
The excitation laser intensity was adjusted so that control signals were minimized near the 
detection limit, but sample signals were maximized near the saturation limit. 
Immunofluorescence 
Oocytes were fixed for 1 hr in 2% formaldehyde in 100mM HEPES, 50mM EGTA, 10mM 
MgSO4, and 0.2% Triton X-100 at 37°C. After fixation, oocytes were incubated in blocking buffer 
(PBS containing 0.01% Triton X-100, 0.1% PVA, and 3% BSA), then in primary antibody, anti-
hnRNP A2 mouse clone EF-67 from Santa Cruz (cat #sc-53531) overnight, diluted 1:200 in 
blocking buffer. Oocytes were washed in PBS containing 0.1% PVA. The secondary antibody, 
anti-mouse FITC obtained from Santa Cruz (cat #sc-2010), was diluted 1:200 in blocking buffer 
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and incubated for 90min. GFP RNA-injected oocytes were incubated overnight and were fixed 
and imaged as above. 
Results 
Figure 1 shows CGG repeat homology profiles for mouse FMR1 RNA, human FMR1 RNA, the 
construct used to generate TG296 transgenic mice and the microinjected CGG99 RNA 
construct. Mouse and human FMR1 RNAs contain the 5’UTR containing CGG repeats, the ORF 
and the RNA sequence downstream of the ORF. Notably, there are fewer CGG repeats in 
mouse FMR1 than in human FMR1 RNA. Consequently, it is unclear whether RAN translation of 
mouse FMR1 RNA is as efficient as human FMR1 RNA. Both mouse and human FMR1 RNA 
are substrates for conventional translation. Human FMR1 RNA with premutation CGG repeats 
may be a substrate for three potential RAN translation products. RAN translation in the GCG 
reading frame can potentially produce a peptide consisting of a poly-alanine tract terminated by 
an in-frame stop codon in the 5’UTR.  RAN translation in the CGG reading frame can potentially 
produce a peptide beginning with a poly-arginine tract and continuing in frame through the 
conventional FMRP translation product, and ending at the conventional FMRP stop codon. RAN 
translation in the GGC reading frame can potentially produce a short peptide poly-glutamine 
tract terminating at a stop codon in the 5’UTR. Each of these RAN translational products could 
potentially be generated in cells from a FXPOI affected individual with CGG repeat expansions 
in the endogenous FMR1 gene. In the TG296 construct conventional translation could also 
initiate at the AUG codon in exon 1 and continue through intron 1 terminating at a stop codon in 
intron 1.  This could potentially produce a partially nonsense translation product. RAN 
translational in the GCG and GGC reading frames for the TG296 construct would be the same 
as for endogenous human FMR1 RNA because the sequence is identical in the 5’UTR. RAN 
translation in the CGG reading frame for the TG296 construct would terminate at the in frame  
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Figure 1: CGG repeat profiles and potential translation products for CGG repeat RNAs. 
CGG repeat homology profiles are shown for mouse FMR1, human FMR1, the TG296 RNA 
construct and the microinjected CGG99 RNA, in order. The blue regions represent the 5’UTRs. 
The red regions represent the ORFs. The gray region in FMR1 is the RNA sequence just 
downstream of the ORF. The green region in the TG296 RNA construct represents intron 1 from 
FMR1. Start codons are located to the left of the box labelled start. Stop codons are located to 
the right of the box labelled stop. Shown above the homology profiles are the potential 
translational products. Conventional translation products are represented by a solid line while 
potential RAN translation products are represented by a dotted line. Start and stop codons are 
indicated where applicable, and the amino acid repeat tract encoded by the repeat region in the 
5’UTR is shown for each RAN translation product.  
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stop codon in intron 1 producing a partially nonsense translation product. The microinjected 
CGG99 RNA contains no start or stop codons in any frame. Therefore, it would not be subject to 
conventional translation. RAN translation in all three reading frames could potentially produce 
poly-alanine, poly-arginine or poly-glutamine. However, with no stop codon, the fates of these 
peptides and the translational machinery associated with them is not clear. Normally, this type 
of RNA would be subject to non-stop decay (NSD), a mechanism for releasing the translational 
machinery from the RNA when there is no stop codon present. However, NSD requires a polyA 
tail (18), and the CGG99 RNA is not polyadenylated. The potential RAN translation products for 
the transgene and for endogenous human FMR1 gene are more similar to each other than the 
potential RAN translation products for microinjected CGG repeat RNA. If granule RNA 
translation is inhibited by RAN translation products by a protein gain of function mechanism then 
translation inhibition in the transgenic mouse oocytes might be similar to translation inhibition in 
human premutation fibroblast cells, as reported in chapter 2. However if granule RNA translation 
is inhibited by CGG repeat RNA by an RNA gain of function mechanism then translation 
inhibition may be similar in transgenic mouse oocytes expressing CGG repeat RNA and in 
oocytes injected with exogenous CGG repeat RNA unless CGG repeat RNA is not exported to 
the cytoplasm or localized in granules in the transgenic oocytes . 
There is conflicting data as to where and when FMRP is expressed in the ovary. Two reports 
show expression of FMRP in oocytes and granulosa cells (4, 19) and one shows FMRP protein 
in granulosa cells but not in the oocyte (20). To resolve this issue, we performed western blots 
on oocytes and granulosa cells for FMRP. We found that oocytes and granulosa cells both 
express FMRP (Figure 2A). Levels of FMRP were significantly higher in granulosa cells 
compared to oocytes confirming previous reports (19). To determine if endogenous FMRP 
expression is affected in TG296 mice (Figure 2B) we analyzed FMRP in granulosa cells.  FMRP  
 
  
81 
 
 
 
 
 
 
 
 
 
 
 
 
  
82 
Figure 2: FMRP and PKR expression in oocytes and granulosa cells. Panel A – Western 
blot analysis of FMRP expression in wildtype (WT) and FMR1 knockout mouse (KO) oocytes 
and granulosa cells. The expected molecular weight for FMRP is 71kDa. Panel B – Western blot 
analysis of FMRP expression in wildtype (WT) and TG296 transgenic mouse granulosa cells. 
Panel C – Western blot analysis of PKR expression in 25, 50 or 250 WT oocytes and 1X or 2X 
mouse brain homogenate. The expected molecular weight for PKR is 58kDa.  
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expression was comparable in both wild type and transgenic granulosa cells, confirming 
previous results that showed similar amounts of FMRP in whole ovaries (19).  
Inhibition of granule RNA translation may be mediated by PKR activation by CGG repeat RNA. 
To determine if oocytes express endogenous PKR, we performed western blots for PKR in 
mouse oocytes (Figure 2C). The results show that PKR is expressed in mouse oocytes 
suggesting that granule RNA translation in oocytes could by inhibited by activation of PKR by 
CGG repeat RNA.  
Oocytes were immunostained for hnRNP A2 to determine if hnRNP A2 is expressed and 
localized in granules in mouse oocytes. Figure 3 shows that hnRNP A2 in oocytes appears 
granular compared to GFP which appears diffuse. The size range of the granular structures 
containing hnRNP A2 in oocytes is consistent with the size of hnRNP A2 RNA granules in 
neurons (0.5-1µm) (15). 
To measure granule RNA translation in oocytes, we microinjected Cy5-labelled RNA encoding a 
Venus-tagged ARC (VenusArc) and imaged the oocytes with confocal microscopy after 
overnight incubation. Although individual granules are difficult to resolve due to the large volume 
of the oocyte and the optical sectioning limitations of the confocal microscope, the injected RNA 
was dispersed throughout the oocyte in a granular distribution (Figure 4C). Expression of 
Venus-ARC detected in the 488 nm channel indicated that the injected RNA was translated in 
oocytes.  
To determine if CGG repeat RNA affects translation in oocytes, Cy5-VenusArc RNA with Cy3-
labelled RNA was co-injected with RNA containing 99 CGG repeats (CGG99). The CGG99 RNA 
also exhibited a granular appearance (Figure 4C). When this RNA was co-injected with 
VenusArc RNA, translation of VenusArc was inhibited. Specific translational activity was 
calculated by dividing whole cell mean fluorescent intensity of VenusArc protein by whole cell 
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Figure 3: hnRNP A2 is granular in oocytes. Immunostaining for hnRNP A2, left panel, shows 
that hnRNP A2 is localized in granule-type structures when compared to GFP, right panel) 
microinjected into oocytes. Scale bar is 25µm. 
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Figure 4: Translation of VenusArc RNA is inhibited in oocytes microinjected with CGG99 
RNA but not in transgenic TG296 oocytes. Panel A, control – Wildtype oocytes were 
microinjected with Venus RNA (green) without CGG99 RNA, left, or with CGG99 RNA (red), 
right. Newly synthesized Venus-ARC protein is shown in white.  Panel B – Cumulative 
Kolmogorov Smirnov plots for specific translational activities (newly synthesized Venus 
protein/microinjected Venus RNA) for oocytes microinjected with VenusArc RNA ± CGG99 
RNA. Panel C – Wildtype oocytes were microinjected with VenusArc RNA (green) without 
CGG99 RNA, left, or with CGG99 RNA (red). Newly synthesized Venus-ARC protein is shown 
in white. Panel D – Cumulative Kolmogorov Smirnov plot for specific translational activities 
(newly synthesized VenusArc protein/microinjected VenusArc RNA) for oocytes microinjected 
with VenusArc RNA ± CGG99 RNA. Panel E – Wildtype oocytes, left, or transgenic TG296 
oocytes were microinjected with VenusArc RNA (green).  Newly synthesized Venus-ARC 
protein is shown in white. Panel F – Cumulative Kolmogorov Smirnov plot for specific 
translational activities (newly synthesized VenusArc protein/microinjected VenusArc RNA) for 
wildtype or TG296 oocytes microinjected with VenusArc RNA. GV is the germinal vesicle and * 
is the oil droplet that enters the oocytes during the microinjection process (17). Representative 
images are shown. Comparable results were obtained with at least 24 oocytes in each 
experiment. 
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mean fluorescent intensity of VenusArc RNA. VenusArc alone had a specific translational 
activity between 1 and 10 while the specific translational activity of VenusArc coinjected with 
CGG99 was usually ~1 (Figure 4D). In contrast, Venus, which does not contain an A2RE and 
therefore should not accumulate in hnRNP A2 RNA granules was not inhibited by coinjection of 
CGG99 RNA (Figure 4A,B). 
To determine if endogenous CGG repeat RNA inhibits granule RNA translation in oocytes we 
microinjected transgenic TG296 and wild type oocytes with VenusArc RNA and compared 
VenusArc translation in each case. We found that transgenic oocytes expressed VenusArc 
protein with comparable specific translational activities as wild type oocytes (Figure 4E,F) 
suggesting that endogenous CGG repeat RNA expressed in TG296 transgenic mouse oocytes 
does not inhibit granule RNA translation.  Possible explanations for the differential effects of 
exogenous and endogenous CGG repeats on granule RNA translation are discussed in the 
following section.  
Discussion 
We have shown that CGG repeat RNA inhibits translation of other RNAs localized in hnRNP A2 
RNA granules in neurons and in oocytes injected with an RNA containing 99 CGG repeats, not 
in the context of FMR1. We have also shown that granule RNA translation is inhibited in human 
fibroblast cells expressing endogenous FMR1 RNA containing a CGG expansion in the 5’UTR 
but not in the transgenic TG296 oocytes containing a truncated FMR1 gene containing exon1 
and part of intron 1. Several possible RNA gain of function or a protein gain of function 
mechanisms for inhibition of granule RNA translation have been proposed.  
If the mechanism for translational inhibition is protein gain of function, then toxic protein 
expressed should be the same in the endogenous FMR1 RNA with CGG repeat expansions in 
human fibroblast cells and in wildtype neurons and oocytes injected with exogenous CGG 
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repeat RNA because translation of VenusArc RNA was inhibited in each case. However the 
toxic protein species should be different in transgenic TG296 mice because translation of 
VenusArc RNA is not inhibited. As described in Figure 1, RAN translation products (which 
represent the potential toxic protein species) are different for human FMR1, for the TG296 RNA 
and the synthetic CGG99 RNA. This suggests that the mechanism for translational inhibition is 
not protein gain of function. 
There are two alternative RNA gain of function mechanisms for inhibition of granule RNA 
translation by CGG repeat RNA. One is competition for translational machinery in the granule.  
Ribosome profiling in chapter 2 showed that ribosomes tend to accumulate in the 5’UTR of the 
FMR1 gene in the region of CGG repeats suggesting that CGG repeats may inhibit granule 
RNA translation by sequestering translational machinery. In this case the CGG repeat region 
would be the part of the RNA that is responsible for sequestering the translational machinery. 
The full length endogenous FMR1 RNA, the transgenic TG296 RNA and the exogenous CGG99 
RNA all contain CGG repeats in the 5’UTR that should be equally capable of sequestering 
translational machinery. Yet, we do not see translational inhibition in the TG296 oocytes. One 
possible explanation may be that transgenic CGG repeat RNA expressed in the TG296 oocytes 
is not exported to the cytoplasm because it lacks appropriate exon-exon junctions, which are 
required for proper splicing and nuclear export.  
A second possible RNA gain of function mechanism is PKR activation by RNA secondary 
structures formed by the CGG repeats. According to this hypothesis, all of the constructs that 
contain CGG repeats should be capable of forming RNA secondary structures that could 
potentially activate PKR and thereby inhibit granule RNA translation. Still, we do not see 
translational inhibition in the TG296 oocytes. So, does this rule out an RNA gain of function 
mechanism? As discussed above, RNAs that are not spliced may become trapped in the 
nucleus of the cell and not exported to the cytoplasm (21). Since the TG296 RNA construct 
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contains a truncated intron 1 from FMR1, It is possible that TG296 transcripts are not exported 
from the nucleus, are not localized to RNA granules, do not activate PKR and therefore do not 
inhibit granule RNA translation. To determine if this is the case, it would be important to use in 
situ hybridization for the TG296 RNA transcript to determine if it is localized to the nucleus or 
the cytoplasm. To distinguish between these two RNA gain of function mechanisms, a PKR 
knockout mouse has been generated and characterized. The PKR KO mouse is physically 
normal, fertile, and produces litters of normal size. PKR KO mice exhibit normal induction of 
Type I IFN by virus and poly(I)poly(C) but a reduced antiviral response by IFN-γ and 
poly(I)poly(C) (22). It would be informative to analyze granule RNA translation in oocytes from a 
PKR KO mouse injected with VenusArc RNA and CGG99 RNA. If granule RNA translation were 
not inhibited this would suggest that PKR activation is responsible for translation inhibition. If 
granule RNA translation is inhibited, this would be consistent with the sequestration of 
translation machinery mechanism. 
One result that supports the PKR hypothesis over the hypothesis for sequestration of 
translational machinery is that translational inhibition in oocytes as seen in Figure 4 of chapter 3 
is less pronounced than translational inhibition in neurons as seen in Figure 3 of chapter 2. If the 
mechanism for translational inhibition were sequestration of translational machinery, there 
would be no obvious explanation for this result. CGG repeats in neurons and oocytes should 
both sequester translational machinery to the same extent. However, if the PKR hypothesis 
were the mechanism for translational inhibition, this could provide a possible explanation 
because levels of PKR are much lower in oocytes than in neurons or fibroblasts. 
We conclude that CGG repeats inhibit granule RNA translation in the context of FXTAS and 
FXPOI most likely by RNA gain of function. Furthermore, it is most likely that CGG repeats 
inhibit granule RNA translation by activating PKR. 
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oocyte injections with some help from Dr. Lisa Mehlmann. I imaged all oocytes on the confocal 
microscope. I was involved in conceptualization and interpretation of all experimental 
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The FXTAS and FXPOI translational phenotype is a granule based phenomenon. 
RNAs are localized in cells, and RNA localization is necessary for localized translation and 
localized protein function (1, 2). An 11 nucleotide sequence known as the A2RE 
(GCCAAGGAGCC) is necessary for dendritic localization of a subset of RNAs in neurons and 
oligodendrocytes (3, 4). The main binding protein for the A2RE is hnRNP A2 (5) which in turn 
binds the multivalent protein TOG (6), which links together multiple RNA molecules in granules. 
CGG repeat RNA also binds hnRNP A2 (7, 8) and is localized in granules (9). CGG repeats in 
the 5’UTR of FMR1 are believed to be causal of FXTAS and FXPOI (10).  
CGG repeats inhibit translation in-cis and in vitro, in a dose dependent manner (11). We show 
for the first time that expanded CGG repeat RNA microinjected into mouse hippocampal 
neurons and expressed in human fibroblast cells (chapter 2) and injected into mouse oocytes 
(chapter 3) inhibits translation of granule RNA in trans and in vivo. This indicates that regulation 
of granule RNA translation by CGG repeat RNA occurs in multiple cell types and may represent 
a widespread physiological regulatory mechanism. Furthermore, since individual granules are 
well resolved in dendrites of mouse hippocampal neurons, we were able to analyze translation 
in individual granules. While translational output from individual RNA granules has been 
explored with single molecule imaging (12), this is the first time that expanded CGG repeat RNA 
has been shown to inhibit translation in individual granules. It is likely that translation inhibition in 
human fibroblasts from individuals with endogenous expanded CGG repeats in the FMR1 gene 
also represents translation inhibition in individual granules (although individual granules are 
difficult to resolve in fibroblasts). We also show that endogenous CGG repeat expansions in 
fibroblast cells affects regulation of calcium transients, a phenotypic effect that may reflect 
translational inhibition of calcium regulatory proteins encoded by granule RNAs in these cells. If 
inhibition of granule RNA translation by CGG repeat expansions represents a pathogenic 
mechanism for FXTAS and FXPOI, this suggests that these are granule based disorders and 
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raises the possibility that translation in granules is normally regulated by CGG repeats in 
unaffected individuals. 
Translational inhibition in FXTAS and FXPOI is an RNA gain of function mechanism. 
Full mutation expansions (usually >200) of the CGG repeat tract in the 5’UTR of FMR1 gene 
cause hypermethylation and transcriptional silencing of the gene (13), resulting in FXS, which is 
considered a protein loss of function disorder.  Premutation expansions (typically between 55 
and 200) are associated with FXTAS and FXPOI (10). In FXTAS and FXPOI, the premutation 
expansion is associated with an increase of FMR1 RNA compared to normal cells, but a 
reduced quantity of FMRP protein (14, 15), suggesting a translational deficit. For this reason, it 
is believed that FXTAS and FXPOI are not protein loss of function disorders like FXS but may 
instead represent RNA or protein gain of function disorders. 
The current controversy in the field is whether FXTAS and FXPOI are caused by RNA gain of 
function or protein gain of function (16). In chapters 2 and 3 we show that synthetic CGG repeat 
RNA, not in the context of FMR1, microinjected into mouse hippocampal neurons and mouse 
oocytes inhibits granule RNA translation. In chapter 2, we show that endogenous CGG repeat 
RNA with premutation expansions inhibits granule RNA translation in human fibroblast cells. 
However, in chapter 3, we show CGG repeat RNA in oocytes from the transgenic TG296 
mouse, containing the 5’UTR, part of the ORF and part of intron 1 from FMR1 does not inhibit 
granule RNA translation. These results are relevant to the question of whether FXTAS and 
FXPOI represent RNA gain of function or protein gain of function disorders. 
The protein gain of function mechanism is based on the idea that repeat associated non-AUG 
(RAN) translation products of FMR1 RNA with expanded CGG repeats have a toxic effect that 
leads to FXTAS and FXPOI (17-19). Based on our results it seems unlikely that RAN translation 
is causing CGG repeat translational inhibition of granule RNAs. We see the same inhibition of 
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granule RNA translation with exogenous CGG99 RNA in neurons as with endogenous FMR1 
RNA with expanded CGG repeats in human fibroblasts. If RAN translation products were 
responsible for inhibition of granule RNA translation, one would expect the RAN translation 
products to be the same or similar for both CGG repeat constructs. Endogenous CGG99 RNA 
can potentially generate three RAN translation products, one in each reading frame. However 
since the exogenous RNA does not contain stop codons in any reading frame it is not clear how 
potential RAN translation products from these RNAs could be released from the ribosome in the 
absence of a termination codon. Endogenous FMR1 RNA in human fibroblast cells can also 
generate three different potential RAN translation products in different reading frames, but these 
RAN translation products would be longer than the synthetic CGG99 RNA products and each 
would terminate at a stop codon. Potential RAN translation products for the transgenic TG296 
RNA are similar to potential RAN translation products for endogenous FMR1 RNA from human 
fibroblast cells except that one would terminate at a stop codon in intron 1 instead of at the end 
of the endogenous FMR1 ORF (Chapter 3 Figure 1). Since granule RNA translation is inhibited 
in human fibroblasts with CGG repeat expansions in the endogenous FMR1 gene but not in 
mouse oocytes with CGG repeat expansion in a transgenic FMR1 construct this argues against 
the idea that inhibition of granule RNA translation by CGG repeat expansion represents a 
protein gain of function mechanism. 
This leaves the possibility of an RNA gain of function mechanism for inhibition of granule RNA 
translation by CGG repeat RNA. In chapter 2 we propose two potential RNA gain of function 
mechanisms. The first potential mechanism involves intra-granule competition between CGG 
repeat RNA and other RNAs for rate-limiting translation machinery in the granule. We show by 
ribosome profiling that density of ribosomes is increased in the 5’UTR CGG repeat region of the 
FMR1 gene, which may reflect RAN translation of CGG repeats or stalled ribosomal scanning in 
this region. In either case, translational machinery could be sequestered in the CGG repeat 
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region of FMR1 RNA, reducing availability for other granule RNAs, thereby inhibiting granule 
RNA translation. The second potential mechanism involves activation of protein kinase R (PKR) 
by CGG repeat RNA in the granule.  RNA encoding PKR contains CGG repeats in the 5’UTR 
(20), which have been shown to be necessary and sufficient for localization and translation in 
hnRNP A2 RNA granules (12). CGG repeat RNA can form double stranded secondary 
structures (21-24) that may bind to and activate PKR in granules. Activated PKR phosphorylates 
EIF2α which forms an inactive complex with EIF2b, inhibiting translation (25).  The results in 
chapters 2 and 3 are generally consistent with either mechanism.   
The following considerations and observations favor the PKR activation hypothesis. CGG repeat 
RNA inhibits granule RNA translation in mouse hippocampal neurons and human fibroblasts by 
more than 10 fold while in chapter 3, CGG repeat RNA inhibits translation in mouse oocytes by 
about 2 fold. This difference in the magnitude of inhibition may reflect differences in PKR 
expression levels in the different cell types. PKR is expressed at lower levels in mouse oocytes 
compared to neurons and fibroblast cells (26-28), which may reduce the magnitude of inhibition 
of granule RNA translation due to PKR activation in oocytes compared to neurons and 
fibroblasts. This favors the PKR activation hypothesis. By contrast, if CGG repeat RNA inhibits 
granule RNA translation by sequestering translational machinery in the granule, one might 
expect that oocytes should have the same level of inhibition as neurons and fibroblasts. 
The PKR activation hypothesis could be tested experimentally in several ways. First, it would be 
important to determine if PKR is actually localized in hnRNP A2 RNA granules. PKR exhibits a 
punctate distribution in human lung cancer cell lines (29, 30) suggesting that PKR is localized in 
granules. Immunostaining for hnRNP A2 and PKR in VenusArc injected neurons would reveal 
definitively if PKR is localized in A2 RNA granules because in neurons, granules are well 
resolved in the dendrites, and ARC RNA and hnRNP A2 provide markers for A2 granules. 
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The following unpublished observations in the Carson lab support the PKR activation hypothesis 
(personal communication). CGG repeat RNA binds to and activates PKR in vitro. CGG repeat 
RNA and PKR inhibit translation in vitro but neither component alone affects in vitro translation. 
In PKR KO cells, EIF2a phosphorylation is reduced. In MSH2 KO cells, which have reduced 
numbers of CGG repeats, PKR activation and EIF2a phosphorylation are reduced. In 
lymphocytes with different number of CGG repeats in the FMR1 gene, PKR activation and 
EIF2a phosphorylation are proportional to the number of CGG repeats in the FMR1 gene. In 
lymphocytes with increased numbers of CGG repeats in the FMR1 gene PKR activation and 
EIF2a phosphorylation are decreased by treating the cells with TMPyP4, which binds to CGG 
repeats. In TMPyP4 treated lymphocytes RAN translation of other CGG repeat RNAs in 
granules is increased. These observations are consistent with the hypothesis that CGG repeat 
RNA inhibits translation in granules by activating PKR. 
Single molecule imaging studies show that translation in granules is bursty, with extended 
periods of low translational activity lasting several minutes interrupted by short periods of active 
translation lasting 1-2 minutes. Cycles of PKR activation/inactivation might provide an 
explanation for bursty translation in granules. Periods of low translational activity might 
correspond to periods when granule RNA translation is inhibited because PKR is activated, 
whereas periods of active translation might correspond to periods when PKR is inactivated. In 
this regard, experimentally measured on-rates and off rates for CGG repeat RNA binding to 
PKR in vitro are consistent with characteristic times for bursty granule RNA translation 
measured in vivo.  It is possible that bursty translation in granules reflects the kinetics of PKR 
activation.  This hypothesis could be tested by analyzing bursty translation in neurons from PKR 
knockout mice (31), and in the presence of various PKR inhibitors (32-35).  
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PKR may be a master regulator for translation in hnRNP A2 RNA granules. 
PKR contains three important domains, essential to its function in regulating translation: a C-
terminal serine threonine kinase domain that activates EIF2α, and two N-terminal double 
stranded RNA binding domains (dsRBDs) that bind to CGG repeat and other double stranded 
RNAs to activate the kinase domain (36). In response to cellular stress, protein activator of the 
interferon induced protein kinase (PACT) protein can activate a protein called transactivation 
responsive RNA binding protein (TRBP), which inhibits PKR by interacting with the dsRBDs, 
even in the absence of double stranded RNA (dsRNA) (37), suggesting a role for PKR 
translational inhibition in response to cellular stress. When either dsRNA or one of these 
proteins is bound to the two dsRBDs, a conformational change occurs that allows for 
autophosphorylation of PKR (38). This allows PKR to phosphorylate EIF2α, a subunit of EIF2 in 
the translation preinitiation complex, which causes it to form an inactive complex with EIF2B that 
no longer functions in preinitiation complex formation necessary for translation (25).  Thus PKR 
activation induced by expanded CGG repeats in FMR1 RNA or by stress, may inhibit translation 
of all other RNA localized in the same granule.  
CGG repeats may mediate homeostatic translational scaling in A2 RNA granules. 
Neurons have developed a system called homeostatic synaptic scaling to sense their level of 
activation and respond to correct their strength (41, 42). Long term potentiation (LTP) and long 
term depression (LTD) are responses by excitatory synapses to strengthen or weaken the 
synapse based on whether calcium entry into the cell is high (LTP) or low (LTD) (40). If LTP 
strengthens the synapse in response to presynaptic and postsynaptic firing, the synapse may 
become too sensitive to excitation, thus creating a positive feedback loop leading to 
unconstrained LTP. The same would be true in the opposite direction with LTD (39). 
Homeostatic synaptic scaling provides a mechanism to avoid “maxing out” or “zeroing out” the 
synapse and maintains synaptic excitability within a range where it can respond appropriately to 
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changes in LTP and LTD (39).  If PKR activation regulates translation in A2 RNA granules, this 
may provide a mechanism for granule homeostatic translational scaling analogous to 
homeostatic synaptic scaling, in response to changes that alter the need for translation 
activation or inhibition. One example is viral infection. If the host cell translates viral RNA, the 
virus will spread, and the cell will die. It has already been shown that PKR is activated in 
response to viral infection (43). It is possible that CGG repeat RNA present in hnRNP A2 RNA 
granules provides a mechanism for regulating PKR activation of translation inhibition and 
maintaining it at a homeostatic level. CGG repeat RNA may regulate PKR activation in A2 RNA 
granules so that the cell can quickly respond with changes to translation. Interferons (IFNs) are 
proteins that are released in response to viral infection. The PKR promoter contains an IFN 
response element, and PKR expression is induced in response to type 1 IFN (43). For these 
reasons, PKR in the cell is believed to mediate an antiviral response when PKR becomes 
activated upon accumulation of viral dsRNAs (44). If PKR activation inhibits granule RNA 
translation in response to CGG repeat RNA expansions, it may also regulate granule RNA 
translation under other circumstances, such as viral infection. Thus PKR may play a role in 
maintaining homeostasis in granule RNA translation.  Under circumstances where granule RNA 
translation is too high PKR activation may decrease granule RNA translation and under 
circumstances where granule RNA translation is too low, PKR inactivation may increase granule 
RNA translation.    
PKR may mediate inter-conversion of A2 RNA granules and stress granules. 
PKR plays a key role in the cellular response to stress (37) and viral infection (44). Formation of 
stress granules may be part of the cellular response to viral infection (45). Stress granules are 
functional RNPs, containing mostly translationally inhibited RNAs (46, 47). Stress granule 
formation is poorly understood, but is believed to involve molecular interactions between 
components of the preinitiation complex (48). Furthermore, the mechanism often involves EIF2α 
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kinase, one of which is PKR (49). If the mechanism for translational inhibition of granule RNAs 
is PKR activation, it is possible that when PKR binds to expanded CGG repeat RNA, it converts 
A2 RNA granules into stress granules as a protective mechanism for the cell. One way to 
investigate this possibility is to look at markers for stress granules in A2 RNA granules in 
FXTAS and FXPOI. Possible markers to look at would be phospho-EIF2α, EIF3, EIF4A1, 
EIF4B, EIF4G, FXR1, G3BP-1 and PABP-1 (50).  
Calcium homeostasis is disrupted by CGG repeat expansions in FXTAS and FXPOI. 
Several RNAs that are involved in regulating calcium homeostasis contain either CGG repeats 
or A2RE sequences (51-53), which mediate localization in A2 RNA granules. Calcium transients 
are increased in astrocytes from CGG knock-in mice (54) and in iPSC derived neurons from 
individuals with CGG repeat expansions in the FMR1 gene (55). This suggests that disruption of 
calcium homeostasis may result from CGG repeat RNA inhibition of granule RNA translation. In 
chapter 2, we show that premutation human fibroblast cells loaded with the calcium indicator 
Fluo-4 exhibit secondary calcium transients in response to Bradykinin, which indicates that CGG 
repeat expansions disrupt calcium homeostasis in premutation fibroblast cells. 
Among the RNAs regulating calcium homeostasis are voltage dependent calcium channel 
(CACNA1A), calcium activated potassium channel (KCNMA1), calcium, calmodulin-dependent 
protein kinase 2A (CAMK2A) and neurogranin (NRGN) (9). CACNA1A mediates entry of 
calcium into excitable cells. KCNMA1 is the pore-forming subunit of the MaxiK calcium-sensitive 
potassium channel. CAMK2A is a serine/threonine protein kinase necessary for LTP and spatial 
learning (56), and NG is a protein kinase substrate that binds calmodulin in the absence of 
calcium (57). One experiment to determine if translation of these RNAs in granules affects 
calcium homeostasis is to systematically knock out each of these genes and to determine if 
calcium homeostasis is restored in human fibroblast cells.  Additionally, it would be important to 
analyze calcium transients in VenusArc injected mouse oocytes with or without synthetic 
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CGG99 RNA. This can be done using thimerosal to induce calcium spikes from internal stores 
in the oocyte (58). If calcium homeostasis is altered in the CGG99 injected oocytes, there may 
be a change in the patterning of the calcium spikes. 
Computational modeling of granules containing CGG repeat RNA and PKR. 
Agent based modeling is a form of computational modeling in which a system is modeled as a 
collection of individual agents, and each agent makes a decision at defined time steps. Agent 
based models keep track of every binding and unbinding event as well as which agents are 
involved (59). This makes agent based modeling very computationally expensive. Rule based 
modeling is a form of computational modeling in which biomolecular reactions are represented 
as a set of local rules (60). These rules define conditions that are both necessary and sufficient 
for the set of interactions and transformations that one wishes to model (61). In other words, 
information that is not pertinent to the system being modeled is left out. For this reason, rule-
based modeling allows some reduction in combinatorial complexity (60). The rules are then 
coupled to rate laws for association and dissociation (61). hnRNP A2 RNA granules lend 
themselves to these computational modeling approaches because granule components, 
including TOG, hnRNP A2 and A2RE RNAs are multivalent and bind to one another under very 
specific conditions. Furthermore, specific and non-specific affinities have been measured for 
many of these components, as have molecule numbers and valencies, providing reasonable 
starting parameters and rate laws (62). 
Falkenberg et al. describes a hybrid deterministic stochastic model for hnRNP A2 RNA granule 
assembly that further reduces combinatorial complexity. The model deconstructs each 
multivalent molecule into its individual binding sites based on the assumption that binding at 
each site is independent of the others. Next, the probability of bond formation at each site is 
calculated deterministically based on all possible interactions at that site. Finally, bound and free 
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states are assigned stochastically, and the granule is reconstructed by identifying which 
molecules are directly or indirectly connected.  
Figure 1A shows the binding sites that were included in the model and the dissociation 
constants associated with each binding pair. TOG is heptavalent, so TOG binding sites are 
represented as multiple individual binding sites with seven times the concentration of intact 
TOG. Each TOG binding site can bind specifically to hnRNP A2 with a 25nM KD or non-
specifically to RNA binding sites with KD ranging from 0.15 to 50µM. hnRNP A2 is bivalent, so 
hnRNP A2 binding sites are represented as individual binding sites with two times the 
concentration of intact hnRNP A2. hnRNP A2 can bind specifically to the A2RE with a KD of 
7nM or non-specifically to RNA with a KD of 1.3µM. Figure 1B is a schematic of some of the 
interactions within a representative granule after reconstruction. Parameter sensitivity analysis 
with this model indicates that the key parameters are: the concentration of the multivalent RNA 
binding proteins and the number of sites available for interaction with other molecules (valency 
of the RNA).  
The key findings from the model are that high affinity binding between hnRNP A2 and TOG and 
between hnRNP A2 and the A2RE allows hnRNP A2 to either promote or inhibit the interactions 
between the other multivalent components in a concentration dependent manner. Figure 2A 
shows that there are five ranges of hnRNP A2 concentration that correspond to simulations in 
which hnRNP A2 concentration differentially affected granule selectivity for A2RE RNA. First, 
when hnRNP A2 and TOG concentrations are very low, there is a low probability of RNA 
interaction driving granule assembly (region I). As the concentration of hnRNP A2 increases, 
this drives interaction between A2RE RNA and TOG, increasing specificity (region II). The 
granule loses this specificity when hnRNP A2 concentration is high enough to drive the 
assembly of all specific and non-specific RNAs into a single large aggregate (region III) as 
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Figure1: Schematic of multivalent interactions in granule assembly modeled in 
Falkenberg et al. This figure is being reused from Falkenberg et al. (62) with permission from 
Elsevier. A) Specific and non-specific interactions between granule components and their 
valency are shown with respective dissociation constants represented by arrows. TOG is 
heptavalent, hnRNP A2 is bivalent and RNAs are allowed variable valency. B) Schematic 
representation of some of the interactions within a representative granule after granule 
reconstruction. 
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Figure 2: hnRNP A2 concentration affects granule specificity. This figure is being reused 
from Falkenberg et al. (62) with permission from Elsevier. A) Selectivity scores are represented 
as a function of hnRNP A2 concentration. Five regions of hnRNP A2 concentration reflect 
scenarios that affect granule specificity. Region V reflects hnRNP A2 concentrations beyond the 
chart. Region II represents an ideal hnRNP A2 concentration that allows granule assembly and 
specificity. B) Percentage of available RNA associated with the largest simulated granule is 
represented as a function of hnRNP A2 concentration. Region III drives assembly into one large 
aggregate. 
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shown in Figure 2B. Eventually, there are so many hnRNP A2 molecules that they saturate both 
RNA and TOG, so hnRNP A2 no longer functions as an intermediate between RNA and TOG 
and granule size is reduced (region IV). Finally, complete saturation of RNA and TOG with 
hnRNP A2 prevents granules from forming (regionV). This defines a narrow region of hnRNP A2 
concentration in which granule specificity occurs. Additionally, low affinity binding between TOG 
and A2RE RNA prevents the RNA from aggregating into an infinitely large complex. These 
findings are based on a model containing only A2RE RNA and non-specific RNA molecules and 
only hnRNP A2 and TOG protein molecules (62).  However the model can be extended to 
include CGG repeat RNA molecules and RNA secondary structure as well as PKR molecules, 
using the same deconstruction/reconstruction strategy. 
CGG repeat RNA is a key component of hnRNP A2 RNA granules. Based on FCS 
photobleaching in chapter 2, we know the ratio of CGG repeat and A2RE RNAs in individual 
granules. We can assume that one hnRNP A2 molecule binds four CGG repeats (by analogy 
with hnRNP A2 binding to A2RE sequences). Therefore, the maximal valency of CGG repeat 
RNAs for hnRNP A2 can be calculated by dividing the repeat number by 4.  It would be of 
interest to introduce CGG repeat RNAs with different numbers of CGG repeats into the model to 
see how granule size and composition are affected. It is possible that introduction of different 
numbers of CGG repeats may affect the ratios of other components in individual granules 
analogous to the way hnRNP A2 concentration defines granule specificity. The most interesting 
result of this scenario would be that the optimal window for CGG repeat number would reflect 
actual CGG repeat numbers in normal individuals. If the model recapitulates granule assembly 
in vivo this could have important implications for regulating granule function. 
Falkenberg et al. suggest that RNA secondary structure in the granule may lower the affinity 
and valency for RNA binding to TOG or hnRNP A2 in vivo and that these effects could be 
represented in the model by altering those parameters (62). CGG repeat RNA is capable of 
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forming secondary structure because CGG repeats can form both hairpins and quadruplex 
structures in vitro (21, 23). By altering the parameters in the model to account for CGG repeat 
secondary structure, we could gain insight into the quantity of hairpin, quadruplex and 
unstructured CGG repeat RNA in the granule. A simple way to approach this would be to add a 
4 CGG repeat motif as a binding site to the model. The CGG repeat could bind to other CGG 
repeats or to hnRNP A2, allowing RNA secondary structure to form or CGG repeat RNA to bind 
to hnRNP A2. This is a realistic first step because hnRNP A2 binds to single stranded RNA (63). 
It would not take into consideration what secondary structure would form if two RNAs on the 
same TOG molecule came into contact with one another, which is something that would 
eventually need to be addressed. This approach is important because if the PKR hypothesis for 
CGG repeat inhibition of granule RNA translation is correct, it is dependent on CGG repeats 
being double stranded. Additionally, two possible outcomes could result from increasing CGG 
repeat number while also allowing CGG repeat secondary structure to form. First, increasing 
CGG repeat number could increase RNA secondary structure to a level that would inhibit 
granule RNA translation by PKR. Second, increasing CGG repeat number could drive granule 
assembly to one large complex as hnRNP A2 concentration did in the Falkenberg et al. model. 
It is possible that CGG repeats regulate PKR activation through alterations in secondary 
structure. 
To determine if this is possible, PKR binding should also be added to the model. Unlike hnRNP 
A2, PKR binds to double stranded CGG repeats (64). Therefore, it would be unnecessary to 
complicate the model by adding activated PKR as a separate PKR species. Instead, PKR 
activation could be represented indirectly by secondary structure formation. In other words, if 
secondary structure is present, it can be assumed that PKR is activated. This approach 
assumes that nothing is competing with PKR for binding to CGG repeat secondary structure. An 
extension of this model would be to consider PKR explicitly and model PKR dimer formation 
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depending on the length of double stranded RNA. Modeling each of these aspects along with 
CGG repeat RNA secondary structure could reveal how PKR affects granule assembly, but 
more importantly, how CGG repeat length and secondary structure affects PKR activation and 
granule RNA translation. 
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